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ABSTRACT 
T-cell function is a promising therapeutic target and remedy in modern 
medicine.  Various ways of modifying T-cell response are under development 
with a view to treating cancer, autoimmune diseases, and transplantation-
related complications. T-cell function can be steered by altering target 
recognition or cosignaling receptors as well as by inducing immunological 
memory or regulatory T cells (Tregs). Unwanted immune responses can be 
curtailed by administering Tregs and, perhaps, long-lasting immunological 
tolerance can be induced. Cytotoxic T cells can be directed against cancer 
cells. Considerable T-cell numbers are required for clinical efficacy. 
Therefore, in vitro cell expansion is often necessary and cultures are 
commonly supplemented with interleukin (IL)-2. As T-cell activation, 
proliferation, effector differentiation, and the development of memory are 
inherently coupled to each other, excessive stimulation during expansion 
may lead to exhaustion. Hence, cells with weaker therapeutic potency may be 
produced. 
In this thesis, various methods of T-cell activation and in vitro cell 
expansion were evaluated particularly in the context of personalized 
medicine and cell therapy. 
Good therapeutic response to T-cell therapy in cancer depends in part on 
the survival of T cells and T-cell memory. The present study demonstrated 
that the proportion of memory T cells could be increased by limiting the 
length of in vitro T-cell expansion and by reducing the amount of IL-2. 
This study further showed that as a result of in vitro expansion Tregs 
expressed higher levels of the Cytotoxic T lymphocyte-associated antigen 4 
(CTLA4) cosignaling receptor. CTLA4 is a central molecule for the Treg-
mediated inhibition. The level of CTLA4 expression in Tregs correlated with 
higher inhibitory function of the cells. Apparently, high CTLA4 receptor 
expression after cell expansion was in part a result of changes in the 
alternative splicing of CTLA4 messenger RNA (mRNA). It was also found 
that the splicing preferences and the expression levels of CTLA4 mRNAs 
were associated with genetic variation in the T-cell cosignaling receptor gene 
region. 
This thesis provides new knowledge that can be applied in the evaluation 
of individual variation in T-cell immunity and the production of therapeutic 
T cells. The T-cell expansion method that was developed here is directly 
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1 REVIEW OF THE LITERATURE 
1.1 T-CELL FEATURES 
T cells are a subpopulation of lymphocytes, white blood cells, that are able to 
recognize specific structures presented by human leukocyte antigen (HLA) 
molecules via the unique T-cell receptor (TCR) found on their surface. T cells 
have three major roles in the immune system (Figure 1). Together with 
antigen-presenting cells (APCs), helper T cells initiate the adaptive arm of 
the immune reaction. The cytotoxic subpopulation of T cells monitors the 
body for infected and transformed cells. Finally, regulatory T cells are able to 
suppress the immune response and generate peripheral immunological 
tolerance. Thus, T cells are indispensable in terms of health (Janeway et al. 
2001). 
Because of the potency of T cells, their functions present both a target and 
remedy to modern, advanced medicine. The improvement of T-cell response 
is pursued in the treatment of infections and cancer to better combat these 
diseases. On the other hand, efforts are made to attenuate the undesired T-
cell reactions in organ and cell transplantation or autoimmune diseases to 
maintain tissue health. In medicine, many features of the T-cell biology could 
be exploited. 
1.1.1 ANTIGEN RECOGNITION 
T-cell progenitors originate from bone marrow hematopoietic stem cells 
(HSC) and mature to functional T cells in the thymus. During maturation, 
each T cell gains its unique receptor for the recognition of antigens (Ag), the 
structures capable of inducing an immune response. The random 
rearrangement of TCR genes provides each T cell a unique TCR with distinct 
specificity for antigens. Before the T cells can leave the thymus, they are 
quality controlled. First, positive selection ensures that the newly generated 
TCRs can bind sufficiently their counter-receptors presenting the Ags, i.e. 
HLA molecules. Then, negative selection results in the deletion of T cells with 
TCR that recognizes self-Ags, antigenic peptides from the own body, thereby 
preventing them from eliciting an autoimmune response. 
Mature T cells circulate in the bloodstream and enter into lymphoid tissues. 
The first signal required for T-cell activation is delivered when a specific Ag, 
which can be recognized by a particular naïve T cell, is presented by HLA 
molecules of an APC. But additional signals are required for proper immune 




Figure 1 The three main functions of T cells. CD4+ T cells, helper T cells (Th), activate other 
immune cells. CD4+ T cells are usually subdivided into different Th classes 
depending on the stimulus they receive and which cells they interact with, e.g.: 
CD8+ T cells and APCs can be activated by Th1-type cells, B-cell activation 
supported by Th2 cells, and neutrophils stimulated by Th17 cells. CD8+ T cells, 
cytotoxic T lymphocytes (CTL), kill their target cells. Immune activation is 
suppressed by regulatory T cells (Tregs). Ag = antigen. 
 
1.1.2 COSIGNALING RECEPTOR CD28 AND CTLA4, ICOS, AND PD-1 
In addition to the Ag-specific signal mediated by TCR and HLA interaction, a 
simultaneous second signal, i.e. cosignal, is needed. Its purpose is to indicate 
danger. Dendritic cells (DCs), which belong to APCs, upregulate CD80 (B7-1) 
and CD86 (B7-2) cosignaling receptor ligands upon final maturation 
following an intake of antigens and migration from tissues to the lymph 
nodes (Table 1). Also, macrophages and B cells, the other APC types, start 
expressing these ligands as a response to immune activation. On T cells, 
engagement of CD28 by CD80 or CD86 provides the essential cosignal for 
naïve T cells. Engagement induces intracellular signaling leading to 
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Table 1 A simplified summary of B7/CD28 cosignaling family molecules. For complete 
review for receptor-ligand interactions and functions, see (Carreno and Collins 
2002) and (Chen and Flies 2013). 
Receptor 
Expression 
on T cells 
Function Ligand(s) Ligand Expression 
CD28 constitutive activating 
CD80, 
CD86 
DCs, B cells, macrophages 
(induced, CD86 constitutively at low 
level);  






induced activating B7-H2 
DCs, B cells, macrophages 
(constitutive), 





DCs, B cells, macrophages 
(induced), 
non-hematopoietic cells (constitutive 
and induced), 
PD-L1 on T cells (induced) 
 
Several families of T-cell cosignaling receptors have been identified (Chen 
and Flies 2013). CD28 belongs to the B7/CD28 family. After the activation of 
T cells by Ag and CD28 signaling, the expression of other family members, 
such as Cytotoxic T lymphocyte-associated antigen 4 (CTLA4), Inducible 
costimulator (ICOS), and programmed death-1 (PD-1), is induced (Carreno 
and Collins 2002, Keir and Sharpe 2005, Bour-Jordan et al. 2011).  They all 
are close homologs of each other, and the genes encoding them are located 
close together. The significance of B7 family cosignaling receptors for the T-
cell response is indicated by detrimental and even fatal outcomes upon 
elimination of their function in animal models. In humans, there is 
substantial evidence that autoimmune susceptibility is associated with 
genetic variation in the T-cell cosignaling receptor genes (Gough et al. 2005, 
Bour-Jordan et al. 2011). The specific genes or mechanisms causing this are 
not known. Since polymorphisms in these genes, for the most part, do not 
change amino acids in the receptor proteins, the association could derive 
from differences in gene expression or splicing (Knight 2005). 
The balance between various signals and the cytokine environment 
determines the functional outcome of the Ag recognition. ICOS further 
enhances T-cell activation. It modifies the cytokine secretion by the T cell 
and may influence the subsequent B-cell response. In contrast, CTLA4 and 
PD-1 counteract the functions of CD28 and ICOS. Both T-cell proliferation 
and cytokine response are inhibited by PD-1 engagement (Carreno and 
Collins 2002). 
The requirement for CD28 signaling, as well as the expression and 
function of the other cosignaling molecules and their ligands, are context 
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dependent. The launching of the effector functions in peripheral tissues, e.g. 
at the site of infection, and the activation of memory T cells (TM) in lymph 
nodes or tissues (described in the following sections), are less dependent on 
CD28 signaling. While CTLA4 probably is pivotal in the regulation of T-cell 
activation in lymphoid tissues, PD-1 and ICOS play a more major role in the 
termination and modification of the response in the periphery (Keir and 
Sharpe 2005, Bour-Jordan et al. 2011). Besides, PD-1 has a role in the thymic 
T-cell maturation process. Last, the induced expression of CD80 on activated 
T cells can add further complexity to the cosignaling network. Engagement of 
T cell-expressed CD80 by PD-L1 or CTLA4 leads to inhibition of T-cell 
growth and effector functions (Chen and Flies 2013). 
1.1.2.1 CTLA4 and its soluble isoform 
The mechanisms behind CTLA4-mediated inhibition are more complex than 
the sole, direct signal-induced alteration in transcription (Bour-Jordan et al. 
2011, Walker 2013). First, CTLA4 was found to increase the T-cell activation 
threshold (the number of engaged TCRs needed), decrease interleukin (IL)-2 
secretion, and to arrest cell cycle (Krummel and Allison 1996, Blair et al. 
1998). Negative signaling inside the T cell by CTLA4 was the obvious 
mechanistic explanation (Rudd and Schneider 2003). Next, CTLA4 was 
found to share its ligands with CD28 and to have a higher affinity for them. 
Therefore, CD28 has to compete for ligands, which results in diminished 
activation signaling. Finally, a ligand-independent function, where CTLA4 in 
the immunological synapse interrupts TCR signaling, has also been proposed 
(Bour-Jordan et al. 2011). 
Regulating the expression of T-cell cosignaling receptors and their ligands 
is central to defining their specific functions. The cell surface expression of 
CTLA4 is under particularly tight regulation by restricted trafficking and 
rapid internalization. The translocalization of CTLA4 to and from the cell 
surface is a prerequisite for its precise function. Therefore, the CTLA4 
receptor mainly has an intracellular localization (Valk et al. 2008, Tai et al. 
2012). 
Functional mechanisms and significance of soluble CTLA4 (sCTLA4), the 
secreted CTLA4 isoform (Magistrelli et al. 1999, Oaks et al. 2000), are not 
well known. sCTLA4 arises from alternative splicing of the CTLA4 transcript 
and lacks the transmembrane domain. As the ligand-binding part is retained, 
sCTLA4 is also able to bind CD80 and CD86. It has been demonstrated to 
have an inhibitory function (Oaks et al. 2000, Huurman et al. 2007, Simone 
et al. 2009, Ward et al. 2013). Many reports have shown sCTLA4 to be 
present in the serum of autoimmune patients (Oaks and Hallett 2000, 
Mayans et al. 2007, Simone et al. 2009, Cao et al. 2012) and one report in the 
serum of leukemia patients (Simone et al. 2012). However, the results have 
been suspected to be a misinterpretation due to unspecific and inappropriate 
test methods. Antibodies recognizing the immunoglobulin (Ig)-like domain 
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of the CTLA4 receptor were utilized in immunoassays that were poorly 
controlled and apparently, instead of sCTLA4, Ig domains of different serum 
proteins were detected (Tector et al. 2009, Esposito et al. 2014). sCTLA4 is 
expressed at a lower level compared to the full-length CTLA4 receptor (Ueda 
et al. 2003, Perez-Garcia et al. 2013). Its expression is either induced (Perez-
Garcia et al. 2013) or repressed (Magistrelli et al. 1999, Oaks et al. 2000) 
upon T-cell activation, depending on the strength of stimulation (Ward et al. 
2013). 
CTLA4 also plays a prominent role in regulatory T cells (Tregs, (Sakaguchi 
et al. 2009)), which is discussed later in this thesis. Current knowledge has 
led to the realization that CTLA4 has a dual role in T-cell immunity (Bour-
Jordan et al. 2011): i) as a T cell-intrinsic regulator in conventional effector T 
cells and ii) as an extrinsic regulator when expressed on Tregs. 
Expression of the inhibitory T-cell cosignaling receptors, such as CTLA4 
and PD-1, which are also called checkpoint molecules, is often induced on T 
cells that have entered into a tumor. This way the tumor avoids being 
destroyed by T cells. Ipilimumab (Ward et al. 2014, Clifton et al. 2015), a 
biological medicine targeting CTLA4 entered European markets in 2011 
(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Public_assessment_report/human/002213/WC500109302.pdf). It is a 
CTLA4 specific antibody (Ab) that is used for the treatment of melanoma. 
Together with other cancer immunotherapies, anti-CTLA4 Abs are 
considered a breakthrough in the field (Couzin-Frankel 2013). It binds to 
CTLA4 and blocks its function. As a consequence, T-cell inhibition is 
abrogated providing stronger T-cell immunity against tumor cells. Another 
mechanism that might operate with anti-CTLA4 monoclonal antibodies 
(mAbs) is related to Tregs. The immunosuppressive microenvironment 
inside tumor tissue induces not only inhibitory molecules but also recruits 
immunosuppressive cells, such as Tregs, to the site. The binding of anti-
CTLA4 mAb to Tregs allows their elimination by Ab-dependent cellular 
cytotoxicity (Clifton et al. 2015). The outcome is the same: enhanced T-cell 
immunity against the tumor. 
Another kind of CTLA4-based medicine, abatacept 
(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Summary_for_the_public/human/000701/WC500048936.pdf), is used in 
autoimmune disorders, e.g. in rheumatoid arthritis (Ward et al. 2014). It is a 
soluble fusion protein of CTLA4 and Ig (CTLA4-Ig). It binds to CD80 and 
CD86 on the surface of APCs, thereby preventing APCs from offering 
costimulatory signals for T cells via CD28. The resulting T-cell inhibition 
ameliorates the autoimmune inflammation. 
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1.1.3 CLONAL EXPANSION AND EFFECTOR FUNCTIONS 
The number of naïve T cells that initially recognize a given antigenic 
structure can be low and insufficient for the elimination of the target.  
Therefore, the activated T cell self-replicates multiple times in order to 
generate a clone of T cells with an identical TCR and specificity against the 
activating antigen. IL-2 delivers this signal required for sustained and 
efficient T-cell proliferation, i.e. clonal expansion. 
The expression of IL-2 and CD25, the α-chain of the heterotrimeric high-
affinity IL-2 receptor, is directly regulated by CD28 signaling (Bour-Jordan 
et al. 2011). The expression of IL-2 and CD25 is induced within hours 
following T-cell activation. Activated T cells are the principal producers of 
this essential cytokine, hence making IL-2 an autocrine T-cell growth factor. 
IL-2 mediates its functions predominantly through the high-affinity IL-2 
receptor. The trimeric receptor is formed by the non-signaling IL-2 receptor 
?-chain, the IL-2 receptor ?-chain and the common cytokine receptor ?-
chain. The binding of IL-2 to CD25 induces a conformational change which 
increases the IL-2 binding affinity for the ?-chain. The ?- and ?-chains, the 
signaling components of the receptor, combine with the initial IL-2 - CD25 
complex. After the cytokine engagement, the cytokine - receptor complex is 
internalized and degraded, except the CD25 subunit which is recycled back to 
the cell surface. A heterodimeric receptor consisting of the ?- and ?-chains is 
also capable of binding IL-2 but only with intermediate affinity. In the 
presence of high IL-2 levels, CD8+ naive and memory T cells can be 
stimulated by the dimeric IL-2 receptor as well. Interestingly, the CD25 
subunit, expressed on the surface of a DC, can upon binding of IL-2 provide 
trans-presentation of the cytokine for the dimeric IL-2 receptor on the T cell 
(Boyman and Sprent 2012).  
After clonal expansion, activated T cells leave the lymph nodes and 
migrate into the inflamed tissues. There they launch their effector functions 
following a re-encounter with their specific target (Figure 1). APCs that are 
located in the tissues present Ags on their HLA class I and II molecules. Also, 
all nucleated cells of the body express HLA class I molecules and can 
therefore directly present intracellular Ags to CD8+ cytotoxic T cells.  
Depending on the T-cell subtype, T cells can either destroy the target 
carrying the specific structure, e.g. virus-infected cell (CD8+ T cells), or 
activate an army of other immune cells to fight against the intruder (CD4+ 
helper T cells). The Ab production of B cells, cytotoxic function of CD8+ T 
cells, further presentation of foreign antigens by APCs, and the activation of 
macrophages to ingest and eliminate microbes are dependent on CD4+ T 
cells. Their effector functions are mediated via cytokines and cell surface 
receptors (e.g. interferon (IFN) ? and CD40L, respectively). 
Recombinant IL-2, aldesleukin, is used in the treatment of melanoma and 
renal cell carcinoma (Boyman and Sprent 2012). The goal is to promote T-
cell and natural killer cell activation and proliferation in order to eliminate 
tumor cells. A severe side effect, a vascular leak syndrome, can be induced 
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when the medicine engages to the high-affinity IL-2 receptor on endothelial 
cells. 
1.1.4 LIMITING THE T-CELL RESPONSE 
Mechanisms for the restriction and termination of the active T-cell response 
are needed to avoid excessive reactions. Peripheral tolerance restrains also 
self-reactive T cells that have eluded thymic negative selection. Both 
inhibitory cosignaling receptors and regulatory T cells play a role here. 
Tregs inhibit the functioning of conventional T cells, and several Treg 
types are known. CD4+CD25+Foxp3+ (Forkhead box p3) Tregs (Sakaguchi et 
al. 2007) represent a constant population in blood and are indispensable for 
the generation of self-tolerance (Sakaguchi et al. 1995). A total of 2-10% of 
CD4+ T cells are Foxp3+ Tregs (Seddiki et al. 2006, Liu et al. 2006). 
Regulatory T cells are discussed in more detail in the latter parts of this 
thesis. 
Upon the termination of an immune response, apoptosis limits the 
number of responding T cells and hence the overall response activity during 
the T-cell contraction phase. Fas (also named CD95) -mediated activation-
induced cell death, which can be triggered by persistent Ag stimulation 
together with IL-2 signaling, causes effector T cells to die in a controlled 
manner.  The survival of effector T cells is also limited by reduced survival 
signaling offered by cytokines. The levels of cytokines and their receptors on 
T cells are strictly regulated to maintain T-cell homeostasis: the secretion of 
IL-2 is ceased by the end of the response and the receptor for IL-7, the most 
important homeostatic cytokine in resting state, is not expressed by effector 
T cells (Rochman et al. 2009, Boyman and Sprent 2012). 
1.1.5 T-CELL MEMORY 
A small share of activated T cells avoids apoptosis and remains in the body as 
memory T cells. They are in a resting state but provide rapid protection 
against recurrent infection by the same pathogen. Due to immunological 
memory, a resistance develops and upon secondary exposure the pathogen 
can often be destroyed before any symptoms occur. 
Memory T cells are further divided into subsets according to their most 
distinctive functions. The cells in the subsets are, however, heterogeneous in 
expression of many cell surface proteins, and particular functions, like 
secretion of certain cytokines, are often overlapping between memory 
subsets. The most primitive subset, T memory stem cells (TSCM), represents a 
subpopulation with self-renewal ability and superior proliferation capacity 
upon stimulation (Gattinoni et al. 2011). TSCM are multipotent; they act as 
progenitors for central memory (TCM) and effector memory T cells (TEM), 
which offer more rapid functional potency. TSCM and TCM home to lymphoid 
tissues where they can be stimulated by their specific Ags if those are 
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presented by APCs. TCM represent ’reactive memory’ (Sallusto et al. 2004): 
they provide efficient proliferation, produce mainly IL-2 and smaller 
amounts of effector cytokines, and differentiate into effector T cells. Based on 
gene expression data and functional studies, the differences between TSCM 
and TCM appear small and mainly quantitative, the main divergence being the 
outstanding competence of TSCM to proliferate. Notably, also TCM are capable 
to self-renew (Busch et al. 2016). TEM provide ’protective memory’: they 
home into inflamed tissues where they are activated by encountering with 
Ags and subsequently launch their immediate effector functions. In 
comparison to TCM, TEM secrete more effector cytokines, like IFN? and tumor 
necrosis factor (TNF), instead of IL-2 (Farber et al. 2014). 
The process for memory T-cell generation is not known but a progressive 
model is surmised. In that model, each less-differentiated T-cell subset acts 
as a precursor for the next one (naïve > TSCM > TCM > TEM > TEff, (Farber et al. 
2014)). 
The efficacy of vaccination is based on immunological memory. The Ags 
administered via vaccination cause at most a mild immune response that still 
allows the generation of memory T and B cells. They patrol the body and can 
offer even life-long immunity. 
1.2 ADOPTIVE T-CELL THERAPY 
Cell therapy can be regarded as a next step in the development of medical 
treatments that so far have included traditional pharmaceuticals (small 
molecules), biopharmaceuticals (therapeutic proteins e.g. antibody), and 
medical devices (Mason et al. 2011). Cells used as medicine differ 
fundamentally from molecule-based medicines because they are living and 
thus able to react to, and be modified by, their changing surroundings 
(Salmikangas et al. 2015). Their long-term effects are difficult, even 
impossible, to test thoroughly in animal models and are thus not yet fully 
established. Therefore there must be a balance between the risks and benefits 
for the patient as well as a comparison to other treatment options. Today, cell 
therapy is predominantly used for severe diseases with an unmet medical 
need. Reflecting the unknown long-term safety profile, early stage clinical 
trials are conducted in target patients instead of healthy volunteers and thus, 
although primarily intended to show safety, also early signals for efficacy are 
sought. 
Adoptive T-cell therapy is defined as the administration of ex vivo 
processed T cells (Figure 2). It provides new treatment options for refractory 
or advanced cancer and infections (Maus et al. 2014) and for controlling 
immune tolerance (Riley et al. 2009). T cells are highly target-specific 
compared to current standard pharmaceuticals e.g. cytostatic drugs or 
immunosuppressants, and thus may cause fewer side effects. On the other 
hand, the extremely complex cellular interactions may lead to unexpected 
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adverse effects.  Intravenous infusion is the usual route for cell 
administration but also local delivery near to the site of action can be used. 
 
 
Figure 2 An illustration of the concept for adoptive T-cell therapy using gene-modified 
chimeric antigen receptor (CAR) T cells as an example. Depending on the T-cell 
product, particular steps can be omitted or modified. Figure from (Barrett et al. 
2014b). 
In this literature review, therapies utilizing only T cells of adaptive immunity 
are discussed, with innate T lymphocytes, such as natural killer T cells and ?? 
T cells, excluded. 
1.2.1 REGULATORY T CELLS 
Inappropriate immune reactions are encountered in allogeneic cell and organ 
transplantations as well as in autoimmune diseases.  Tissue damage is caused 
particularly by T cells that specifically attack harmless targets either on 
transplanted allogeneic organs or cells (rejection), on tissues  of the 
allogeneic stem cell recipient (attacked by the T cells in the graft, graft-
versus-host disease, GVHD), or on body’s own tissues (autoimmunity, e.g. 
destruction of the insulin producing cells in type 1 diabetes, T1D). Current 
treatment options, such as life-long immunosuppressive medication and 
other immunomodulatory agents (e.g. thymoglobulin), are not specific but 
induce a general decline in immunity increasing the risk for infections and 
cancer. In addition, despite insulin replacement therapy, a major proportion 
of T1D patients suffer from serious secondary complications. Severe GVHD 
represents an unmet clinical need that may lead to death. In these situations, 
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regulatory T cells may offer a way toward long-lasting immunological 
tolerance. 
1.2.1.1 Clinical experience: safety and efficacy 
During the last seven years, about a dozen clinical trials have been conducted 
to test the safety and potency of Tregs for clinical therapy (Trzonkowski et al. 
2015). General immune suppression, similar to current immunosuppressive 
regimens using traditional pharmaceuticals, and the possible induction of 
immune activation due to effector T cell impurities in the Treg product or 
unstable Treg identity, have been identified as potential concerns. 
Administering Tregs seems safe according to the results from patients with 
GVHD (90 patients in six centers, (Trzonkowski et al. 2009, Edinger and 
Hoffmann 2011, Brunstein et al. 2013, Martelli et al. 2014, Bacchetta et al. 
2014, Theil et al. 2015)), autoimmunity (46 patients in three centers, T1D 
(Marek-Trzonkowska et al. 2014, Bluestone et al. 2015) and Crohn’s disease 
(Desreumaux et al. 2012)), and in liver transplantation (10 patients in a 
single study, (van der Net et al. 2016)).  Though a malignant disease was 
developed in two GVHD patients (Theil et al. 2015) the causal connection to 
Tregs or to the immunosuppressants commonly in use is unclear. However, 
regarding general immune suppression, it is too early to draw conclusions 
about long-term safety, since the follow-up period for most patients has been 
at most one year (Trzonkowski et al. 2015), except for one study with the 
follow-up of seven years (Bacchetta et al. 2014). In many trials, the 
persistence of Tregs has been poor, thus not necessarily revealing the whole 
picture of the long-term safety. 
Tregs have been used as both the treatment and prophylaxis for GVHD 
(Trzonkowski et al. 2015). The prophylactic approach, where Tregs are 
administered either at the time of HSC transplantation (Brunstein et al. 2011, 
Brunstein et al. 2013, Martelli et al. 2014) or a few months after (Edinger and 
Hoffmann 2011, Bacchetta et al. 2014), seems most promising. The rationale 
behind the procedure is two-part: i) immune suppression induced by Tregs 
directly hinders alloreactive GVHD-causing T cells, and ii) faster immune 
reconstitution due to tapering of immunosuppressive medication strengthens 
protection against infections and enhances the desired graft-versus-leukemia 
effect, thus also lowering the risk for relapse.  
In autoimmune disorders, adoptive Tregs have shown early potency in 
patients with Crohn’s disease (Desreumaux et al. 2012) and T1D (Marek-
Trzonkowska et al. 2014). Expectations are high since, in preclinical animal 
models, existing autoimmune diseases have not only been suppressed but 
reversed (Tang et al. 2004). 
In summary, clinical data for adoptive Treg therapy is scarce and study 
protocols so variable, that the definitive proof of efficacy has yet to 
materialize. 
Review of the literature 
20 
1.2.1.2 Mechanisms of action 
Regulatory T cell may be defined as a T cell exerting inhibitory function. 
However, two cell types are used in the clinic (Trzonkowski et al. 2015), 
CD4+CD25+Foxp3+ Tregs (Sakaguchi et al. 2007) and T regulatory type 1 
cells (Tr1, (Vignali 2008)). 
Foxp3+ Tregs differentiate into Tregs during maturation in the thymus. 
Alternatively, these cells are induced from conventional CD4+ T cells in 
response to TCR stimulation combined with Transforming growth factor ? 
signaling (Th3, (Vignali 2008)). The transcription factor Foxp3 is imperative 
for the Treg generation in the thymus and their functional activity (Hori et al. 
2003, Fontenot et al. 2003, Khattri et al. 2003).  
Tr1 cells are conventional peripheral CD4+ T cells (non-Tregs) that are 
induced by IL-10 and have a suppressive function.  With IL-10 secretion as 
their main mechanism, they typically do not express Foxp3 (Vignali 2008). 
The main difference between thymic and peripheral Tregs (both 
Foxp3+and Tr1) is the source of Ags that their TCRs recognize: self-Ags for 
thymus derived Tregs and foreign Ags for peripherally derived Tregs. 
Suppressive function is not confined to the recognized Ag but, similarly to 
conventional T cells, Tregs need activating signals to execute their functions. 
Therefore the choice of polyclonal or Ag-specific Tregs may be an important 
factor determining clinical efficacy (Trzonkowski et al. 2015, van der Net et 
al. 2016). 
Foxp3+ Tregs employ multiple immunosuppressive mechanisms, both cell 
contact dependent and mediated by soluble factors (Figure 3). Effector T 
cells are either directly inhibited by Tregs or indirectly via APCs. The 
particular mechanism(s) in use may depend on the context (anatomical 
location or disease), the Treg subtype, and the target cell characteristics. 
They may also be deployed sequentially (Vignali 2008). However, the 
CTLA4-related mechanisms seem to be shared by all Foxp3+ Tregs 
(Sakaguchi et al. 2009, Walker 2013). 
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Figure 3 Immunosuppressive mechanisms of Foxp3+ Tregs. Figure from (Vignali 2008). 
1.2.1.3 CTLA4 in Treg function 
The deletion of CTLA4 function leads to uncontrolled, detrimental T-cell 
proliferation in mice (Waterhouse et al. 1995). Effector T cells expressing 
CTLA4 were found to be inhibited by CTLA4 ligation (Walunas et al. 1994), 
revealing its cell-intrinsic role in the regulation of T-cell homeostasis (Bour-
Jordan et al. 2011). CTLA4 was defined as a negative cosignaling receptor for 
T-cell activation. Due to the strong genetic association (Ueda et al. 2003, 
Haimila et al. 2004), the CTLA4 gene region is considered a general 
autoimmune susceptibility region (Gough et al. 2005). Autoimmune-related 
functional and numerical Treg impairment (Dejaco et al. 2006) and the 
constitutive, Foxp3-controlled CTLA4 expression in Tregs (Miyara et al. 
2009, Sakaguchi et al. 2009) led to the understanding of the key role CTLA4 
plays in Tregs (Walker 2013). The phenotype of Treg-specific CTLA4 deletion 
that is characterized by a broad immune dysregulation is similar to Foxp3-
defective mice and humans (Brunkow et al. 2001, Bennett et al. 2001) and 
points to the essential function of CTLA4 in sustaining self-tolerance (Wing 
et al. 2008). 
The cell-extrinsic CTLA4 function means that immune-controlled T cells 
do not have to express CTLA4 themselves (Bour-Jordan et al. 2011). Several 
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detailed mechanisms for CTLA4-mediated inhibition in Tregs have been 
proposed (Figure 4, (Sakaguchi et al. 2009)).  First, CTLA4 can outcompete 
the activating CD28 for the cosignaling receptor ligands, CD80 and CD86. 
This mechanism may still mainly work in cell-intrinsic fashion on effector T 
cells. Second, in order to abolish the activation of T cells, CTLA4 on Tregs 
directly removes these ligands from the surface of APCs by trans-endocytosis 
(Qureshi et al. 2011). Third, CTLA4-provoked events in the APC induce 
indoleamine 2,3-dioxygenase (IDO), a tryptophan-depleting enzyme that 
engenders immune restraint (Fallarino et al. 2003, Grohmann et al. 2003, 
Cribbs et al. 2014). The depletion of the essential amino acid tryptophan and 
the action of its proapoptotic metabolites, kynurenines, mediate the 
inhibition. 
The sCTLA4, an alternatively spliced isoform (Magistrelli et al. 1999), also 
has the ability to engage with CD80 and CD86 (Oaks et al. 2000). In a 
diabetogenic mouse model, the expression of CD86 on the APC surface was 
downregulated by Treg-secreted sCTLA4 (Gerold et al. 2011). The inhibitory 
function of mouse and human Tregs is diminished by specific elimination of 
sCTLA4 and in murine models, this leads to autoimmunity and reduced 
tumor control (Gerold et al. 2011, Ward et al. 2013). 
 
 
Figure 4 CTLA4-mediated inhibitory functions and IL-2-related effects of Foxp3+ Tregs. 
Figure from (Sakaguchi et al. 2009). 
1.2.1.4 IL-2 and Tregs 
Shimon Sakaguchi originally revealed the existence of Foxp3+ Tregs by 
demonstrating that constitutively CD25-positive CD4+ T cells are 
indispensable for the generation of normal self-tolerance (Sakaguchi et al. 
1995). Only later, Foxp3 was found to be a better Treg marker, although still 
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not exclusive (Hori et al. 2003). CD25, the IL-2 receptor ?-chain, is one of 
the three IL-2 receptor components, which together form the high-affinity 
IL-2 receptor. The ?-chain provides high-affinity binding for the receptor 
upon cytokine engagement. The other receptor chains, the IL-2 receptor ?-
chain and the common cytokine receptor ?-chain, which are expressed by 
Tregs as well, are responsible for the signal transduction (Boyman and 
Sprent 2012). In Tregs, the transcription of CD25 and the repressed 
expression for IL-2 are directly controlled by Foxp3 (Figure 4, (Sakaguchi et 
al. 2009)). Signaling through the IL-2 receptor is crucial for the survival of 
Tregs and a deficiency of IL-2 or CD25 disrupts self-tolerance (Malek and 
Bayer 2004). Because of their high dependency on IL-2, Tregs act as IL-2 
sinks. Therefore, also CD25 contributes to the T-cell suppression by limiting 
IL-2 availability. Besides, signaling through the IL-2 receptor boosted Treg 
function via STAT5 activation (Chinen et al. 2016). 
Interestingly, Tregs simultaneously represent both an anergic (no/low IL-
2 production in response to Ag) and in terms of conventional T cells, an 
activated phenotype (e.g. expression of CD25, CTLA4, and Foxp3 and 
repressed expression of CD127, the IL-7 receptor). Epigenetic control by 
demethylation of the Foxp3 gene plays a key role in the stable and 
constitutive expression of these downstream genes (Floess et al. 2007). 
1.2.1.5 Treg production 
Blood has normally been used as starting material for Treg generation, 
except for one study that utilized cord blood derived Tregs (Brunstein et al. 
2011). The donor of the starting material depends on the treatment 
indication. The patient’s own autologous blood has been used in the cases of 
autoimmunity and organ transplantation while blood from the original donor 
for the HSC transplantation has been used in a GVHD setting. Tregs that 
have been tested in patients can be roughly categorized into four groups 
based on their method of production (Trzonkowski et al. 2015): 
i. fresh polyclonal Foxp3+ Tregs that are administered directly 
after enrichment without further in vitro expansion, 
ii. expanded polyclonal Foxp3+ Tregs, 
iii. alloantigen-specific Foxp3+ Tregs, and 
iv. polyclonal or Ag-specific Tr1 cells (Table 2). 
 
Clinical data from the trials using alloantigen-specific Foxp3+ Tregs (iii) 
have yet to be published. 
In general, methods for the production of polyclonal Tregs are simpler 
than for Ag-specific Treg cells (Tang and Bluestone 2013, Putnam et al. 2013, 
Trzonkowski et al. 2015, van der Net et al. 2016). Also, the Ag-specific 
protocol carries the risk for cellular impurities, in forms of allogeneic APCs, 
with potentially harmful effects. Often at least two rounds of activation are 
needed for sufficient Treg expansion (Putnam et al. 2009, van der Net et al. 
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2016). The total processing time for the expanded products varies from two 
up to eight weeks. The anticipated Treg cell numbers needed for treatment 
might be higher in the polyclonal setting due to the weaker activation 
stimulus provided in vivo (Tang and Bluestone 2013). The numbers of fresh 
Tregs directly enriched from blood (Edinger and Hoffmann 2011, Martelli et 
al. 2014) are considered insufficient for effective clinical therapy for most 
applications (Riley et al. 2009, Edinger and Hoffmann 2011, Tang and 
Bluestone 2013). 
 
Table 2 Technical steps for different Treg production methods. 
 Treg types used for therapy 








? methods for selection ? CD8
+ elimination ? CD25+ enrichment (MACS) 




beads allo APCs APC/feeder* 
& IL-10 
± Ag # expansion CD3/CD28 beads ^ 
* autologous or allogeneic depending on the setting 
^ not always used for alloAg-specific Tregs 
# if Ag-specific Tregs are produced (Desreumaux et al. 2012) 
FACS = fluorescence-activated cell sorting, MACS = magnetic cell sorting, MNC = mononuclear cells. 
1.2.2 ANTIGEN-SPECIFIC EFFECTOR T CELLS 
The TCR repertoire of mature T cells has a theoretical potential to recognize 
all imaginable peptide fragments that are not of normal self-origin, naturally 
including pathogenic peptides as well. Thus, T-cell reactivity against some 
transformed self-derived proteins exists as well, enabling tumor cell 
immunosurveillance (Dunn et al. 2002). 
In addition to pathogen-specific T cells and tumor-infiltrating 
lymphocytes (TILs) discussed in detail below, the generation of tumor Ag 
specific T-cell clones derived from blood represents a less frequently used 
approach (Hunder et al. 2008). 
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PATHOGEN-SPECIFIC T CELLS 
After hematopoietic stem cell transplantation, slow immune reconstitution 
leaves the patient susceptible to normally harmless infections. These 
infections are one of the main causes of transplant-related mortality. Current 
anti-viral medicines have a limited applicability and efficacy in this severely 
ill and specific patient population.   Patients may suffer viral and fungal 
infections, and T cells specific for these pathogen types could be used for 
therapy. In the course of 20 years, Epstein-Barr virus (EBV), 
cytomegalovirus (CMV), and adenovirus have been the most frequent targets 
(Saglio et al. 2014). While Aspergillus-specific T cells would fulfil an unmet 
clinical need (Papadopoulou et al. 2016), only one clinical study has been 
published so far (Perruccio et al. 2005). 
The original donor for the HSC transplantation is used as the source for 
the pathogen-specific T cells. A more recent approach is to use third-party 
donors allowing banking of virus-specific T-cell products. In this setting, 
GVHD avoidance requires either careful matching for the tissue types or 
strict selection for the virus-specific T-cell lines. Previous exposure to the 
specific pathogen is required for the donor to be eligible. Blood-derived cells 
are either activated with pathogenic peptides, with responding cells selected 
based on their IFN? secretion, or alternatively they may be selected directly 
through the binding of their TCR to tetramers mimicking HLA-Ag peptide 
complexes. The processing takes one day, making the T-cell products rapidly 
available (Saglio et al. 2014). 
Protective immunity against Aspergillus is mediated through CD4+ Th1-
type T cells and their cytokines (IFN? and TNF). In contrast, for the most 
part, CD8+ T cells are pursued for viral infections owing to their direct 
cytotoxic functions against infected cells. 
Worldwide, hundreds of patients in phase I trials have received pathogen-
specific T cells after allogeneic HSC transplantation either as prophylaxis or 
for treatment. Occurrence of GVHD in CMV-targeting therapy is a potential 
concern and wider clinical benefit still remains uncertain. EBV therapy is 
safe and evidence for its clinical efficacy is strong (Saglio et al. 2014). 
A novel endeavor is to use autologous virus-specific T-cells against 
malignancies that carry viral Ags but the efficacy of this concept has not yet 
been proven in the clinic (Schuessler et al. 2014). 
TUMOR-INFILTRATING LYMPHOCYTES 
The hypothesis that immune system could inhibit or prevent tumor 
development was presented in 1909 by Paul Ehrlich and then by Burnet and 
Thomas in 1957 through the concept of lymphocyte tumor 
immunosurveillance (Dunn et al. 2002). Indeed, the number of lymphocytes 
that naturally infiltrate into the tumor tissue in melanoma and several other 
types of solid cancer correlates with longer patient survival (Dunn et al. 
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2002). Thus, at least some of the infiltrated lymphocytes are expected to 
specifically recognize and destroy tumor cells. 
The first clinical study of adoptively transferred TILs was published in 
1988, reporting a significant but brief treatment response (Rosenberg et al. 
1988). Since then patient preconditioning and IL-2 administration for the 
induction of a long-term response have been conceived as parts of TIL 
therapy. Early-stage TIL trials in metastatic melanoma, in which altogether 
over 300 patients were treated, showed reproducible response rates between 
20 to 72%, with a mean of ~50% (Besser et al. 2015). TILs are often used as 
salvage therapy when the disease is refractory to other treatments. 
Considering the patients’ clinical status, and the up to 10 year disease-free 
survival times seen in some of the patients (Rosenberg et al. 2011), the 
efficacy is impressive. Administration of TILs as such seems safe but severe 
toxicities, induced by the lymphodepletive preconditioning and high-dose IL-
2 administration after TILs, can be expected. On-target but off-tumor 
autoimmunity occurs as a direct adverse effect of TILs when the TILs target 
tumor-associated, but otherwise normal self-Ags, such as the differentiation 
Ag Melanoma antigen recognized by T-cells 1 (MART-1, (Dudley et al. 
2002)). The autoimmunity detected against melanocytes in eyes, ears and 
skin has, however, been reported to be transient. 
The clinical success of TILs has been confined to melanoma, although the 
treatment of other solid cancers has been actively explored for two decades 
(Besser et al. 2015). In melanoma, the three key determinants for successful 
TIL therapy are fulfilled: safe access to the patient’s tumor tissue, active T-
cell infiltration into the tumor, and high mutation rate in the tumor cells 
(Lawrence et al. 2013). Mutations increase tumor immunogenicity by 
providing novel, tumor-specific antigenic peptides, i.e. neoantigens. A novel 
approach is to utilize the viral specificity of TILs against virus-induced 
cancers, such as papilloma-associated malignancies (Stevanovic et al. 2015). 
Generation of TILs for adoptive therapy starts with a tumor biopsy. Tissue 
fragments are cultured in vitro until cells that had infiltrated into the tumor 
outgrow from the tumor cell mass. Either standard or so-called ‘young’ TILs 
can be generated (Tran et al. 2008). ‘Young’ TILs are cultured at this stage 
for 10-18 days, and all separate lymphocyte cultures with different Ag-
specificities are pooled. The standard TIL protocol takes additional 10-18 
days during which expansion and selection of tumor-reactive clones is 
performed. Finally, both TIL types are further expanded for two weeks by a 
rapid expansion protocol (REP). In summary, TILs are autologous, 
heterogeneous lymphocytes of intratumoral origin that are expanded in vitro 
for five to seven weeks (Besser et al. 2015). 
The direct killing activity of CD8+ T cells due to the TCR-specific 
recognition of tumor Ags is the apparent functional mechanism of TILs. 
However, the depletion of CD4+ T cells from the TIL products may weaken 
therapeutic potency (Dudley et al. 2013). Furthermore, a patient with 
advanced gastrointestinal carcinoma was treated solely with CD4+ TILs 
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specifically recognizing a neoantigenic mutation in the receptor tyrosine- 
protein kinase ERBB2 interacting protein (ERBB2IP, (Tran et al. 2014)). 
Transferred CD4+ cells produced Th1 cytokines, IFN?, TNF, and IL-2, and 
expressed cytotoxic activity, leading to long-lasting tumor regression. 
1.2.3 GENE-MODIFIED T CELLS 
One restriction of the TIL approach is the lack of tumor immunogenicity. 
First, most tumor-associated Ags are normal self-Ags. T cells with TCRs that 
strongly recognize self-Ags are deleted in the thymus during T-cell 
maturation. Thus, many tumors do not bear immunogenic proteins. Second, 
tumor cells gain advantage by impairing intracellular Ag processing and/or 
HLA I presentation, thus avoiding T-cell recognition. Genetic instability in 
rapidly dividing tumor cells offers an opportunity for such development. Also 
the immunosuppressive tumor microenvironment limits Ag presentation. 
Third, these immunosuppressive soluble factors and cells inhibit the 
maturation and function of APCs (Kaufman and Disis 2004). As a result, in 
many tumor biopsies effective TILs are difficult to find. 
Genetic engineering of cells provides tools for synthetic reconstruction of 
T cells with desired Ag-specificity. The gene fragments or constructs can be 
introduced into cells with several methods (Maus et al. 2014): with 
chromosome-integrating viral vectors (gammaretroviral, lentiviral), with 
transposons for permanent gene transfer, or with non-integrating methods 
for transient expression of the gene (adenoviral vectors, RNA transfection). A 
risk for the induction of malignant transformation through replication-
competent virus and insertional mutagenesis is among the major safety 
concerns linked to therapies using genetic modifications. This risk has been 
addressed by modern vector technology with the split-genome design, which, 
by deleting required elements from the vectors, eliminates the potential for 
replication, and with self-inactivating vectors enabling the vector genome 
activation (Bear et al. 2012, Schambach et al. 2013). 
T-CELL RECEPTOR (TCR) –ENGINEERED T CELLS 
The molecular characterization of tumor-recognizing TCRs on TILs and the 
advances in gene therapy allowed in vitro engineering of therapeutic cells. 
Any particular TCR with a known specificity can be inserted into T cells 
derived from the patient’s blood, regardless of the T cells’ original 
specificities. This genetic engineering process redirects naturally existing T 
cells against a new, desired target. Consequently, availability of tumor-
specific T cells, a critical aspect in the TIL therapies, could be achieved. Thus, 
TCR-engineered T cells, also called TCR-modified T cells, are being 
developed against various malignant disorders (Ikeda 2016). 
A MART-1 specific TCR identified in TILs from a melanoma patient was 
used in the first TCR-engineered clinical study (Morgan et al. 2006). The 
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TCR sequence was incorporated into T cells of metastatic melanoma patients 
using a gammaretroviral vector. With a response rate of 13%, only modest 
clinical efficacy was attained and no adverse reactions were detected. The 
clinical response rate was increased to 30% in another set of patients using a 
high-affinity TCR for the same Ag (Johnson et al. 2009). This time, 
autoimmunity that was similar to but more severe than with MART-1 
targeting TILs was seen. 
Naturally existing TCRs against tumor-associated self-Ags (as in many 
TILs) commonly bind their targets with only low to intermediate affinity. To 
achieve better clinical outcomes with TCR-engineered T cells, their affinities 
have been frequently enhanced either through genetic modification of the 
original TCR sequence or by immunizing mice (i.e. using mouse-derived TCR 
sequence). However, use of such affinity-enhanced TCRs significantly 
increases the risk for adverse effects, since such reactivity has never existed 
in humans (Ikeda 2016). 
Although the goal is to broaden the applicability of adoptive T-cell therapy 
to other cancer types, in the clinical trials using TCR-engineered T cells 
>60% (n=88) of patients have suffered from melanoma (Ikeda 2016). Among 
the twelve early-stage clinical trials, hematologic, breast, colorectal, 
esophageal, and synovial cell cancers have been the other targets (Maus et al. 
2014, Ikeda 2016). Results from these trials show response rates between 
11% and 80% (mean ~40%). Very encouraging results (80% response rate, 
70% with complete response) were obtained in tumor antigen NY-ESO-1 -
targeted myeloma study conducted along with autologous HSC 
transplantation (Rapoport et al. 2015). The expected response rate with the 
standard care utilizing autologous HSC transplantation alone is less than 
40%. The use of TCR-engineered cells was safe, and GVHD encountered in 
patients was shown to be caused by the standard autologous HSC 
transplantation. 
Severe adverse effects including deaths have occurred with TCR-
engineered T-cell therapies. In contrast to TIL treatment, these side effects 
have arisen directly from the adoptively transferred T cells – and their TCR 
specificity. Affinity-enhanced TCR recognizing melanoma-associated antigen 
MAGE-3 caused cardiac toxicity and two patients died (Linette et al. 2013). 
Engineered T cells cross-reacted with a peptide derived from an unrelated 
titin protein that is expressed in the cardiac muscle (Linette et al. 2013, 
Cameron et al. 2013). This off-target reaction was induced by a titin-derived 
peptide with limited sequence similarity to MAGE-3 (5 of 9 amino acids). 
Two more deaths occurred using another type of affinity-enhanced MAGE-3 
reactive T cells (Morgan et al. 2013). Neurological toxicity was caused by on-
target but off-tumor T-cell reactivity due to unforeseen MAGE expression in 
the brain. 
TCR cross-reactivity appears completely physiologically in nature (Mason 
1998). It may cause potential off-target risks in T-cell therapies. Normal 
tissue expression of targeted Ags may cause on-target off-tumor risks. The 
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development of TCR-engineered T cells requires extensive, complicated, and 
laborious preclinical testing for the prediction of concomitant side effects 
(Linette et al. 2013, Cameron et al. 2013, Morgan et al. 2013, Ikeda 2016). 
Unfortunately, preclinical animal models are not useful (Maus et al. 2014). 
Thus, several types of safety switches have been developed and introduced 
into the engineered cells in order to eliminate rapidly the transferred cells if 
severe or uncontrolled adverse reactions occur (Jackson et al. 2016). Even so, 
careful anticipation of the risks is a prerequisite when novel TCR-engineered 
T-cell types are clinically tested. 
A shortcoming of TCR-engineered T-cell therapy is its HLA-restricted 
nature. When T cells recognize their specific antigenic peptide through TCR 
binding, they simultaneously bind to the HLA molecule presenting the 
peptide. This binding to the HLA molecule is also TCR specific, meaning that 
a particular T cell can only recognize the specific Ag in combination with a 
particular HLA type. Therefore, the HLA type recognized by the TCR to be 
used needs to be known - and the recipient of the cells must carry this HLA 
type. Fortunately, extensive HLA matching covering also other HLA loci, 
required in, for example, allogeneic cell or organ transfer, is not needed. 
Most of the TCRs utilized recognize HLA-A2 molecules, which are found in 
~50% of Caucasians (Ikeda 2016). 
In protocols for the production of TCR-engineered T cells, peripheral 
blood is used as starting material (usually obtained by apheresis), T cells are 
activated with an anti-CD3 antibody that binds to the endogenous TCR 
complex, and viral vectors are used for the permanent insertion of the 
additional TCR gene into the chromosomal DNA. In vitro culture of the cells 
takes 7 to 10 days. One center has used an additional 14 day REP protocol for 
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cell surface Ags 
cell surface Ags 
protein protein protein, lipid, glycan 
requirement for natural 






safety in regard to 
target specificity 
least risky most risky small risk 
 
CHIMERIC ANTIGEN RECEPTOR T CELLS 
The main obstacle for overcoming cancer with immunotherapies is the 
immunosuppressive microenvironment created by the tumor. As a result, 
antigen presentation is inhibited (Kaufman and Disis 2004, Munn and 
Bronte 2016). Both TILs and TCR-engineered T cells are dependent on Ag 
presentation carried out either directly by tumor cells or APCs (Table 3). 
Gene technology also allowed the utilization of non-T-cell derived Ag-
binding receptors in T cells. Usually Ag-specificity is achieved by exploiting 
antibodies but also protein ligands can be used (Brown et al. 2015, Jackson et 
al. 2016). In contrast to TCRs recognizing processed linear peptides, B cells 
secrete antibodies that specifically recognize unprocessed, three-dimensional 
structures. T cells can be activated through antibody-based Ag recognition by 
connecting antibody segments with the CD3? domain from the TCR complex, 
a signaling domain that normally delivers the signal into the T cell ((Gross et 
al. 1989), Figure 5). Thus, T cells can be specifically activated by cell surface 
molecules without Ag processing and presentation or HLA restrictions. The 
requirement for Ag presentation for adoptive T-cell therapies is thus 
abrogated. These synthetic receptors were first named T-bodies and later 




Figure 5 a) Endogenous T cells, such as TILs, recognize target Ags with their TCR. The 
associated CD3 receptor complex, particularly the CD3? domain, transduces the 
signal into the cell. TCR-engineered T cells use the same system for Ag recognition 
although the TCR itself is genetically modified and artificially incorporated into the 
cell. b) CAR T cells commonly utilize Ab-derived segments (heavy and light chain 
single-chain variable fragments (scFv)) for Ag binding. First generation CARs 
contained a single signaling domain, CD3?. In the second and third generation 
CARs one or two additional signaling domains are added. These domains are 
derived from T-cell cosignaling receptors, such as CD28 or 4-1BB. Figure from 
(Maus et al. 2014). 
1.2.3.1 Safety 
Although cancer is the obvious target for CAR T-cell therapy, persistent 
infections could be treated with it as well. In fact, first clinical CAR T cell trial 
was against human immunodeficiency virus (HIV) infection (Mitsuyasu et al. 
2000, Deeks et al. 2002). CARs in these trials did not use antibody-based 
recognition; instead the natural HIV envelope receptor CD4 was used as the 
extracellular, Ag-binding part. It was connected to the CD3? domain and the 
idea was to eliminate HIV envelope expressing, i.e. HIV infected T cells. Only 
a modest effect on viremia was observed. Importantly, long-term safety of 
gene-modified T-cell therapy was demonstrated in these trials (Scholler et al. 
2012). During a follow-up period of 11 years in 43 patients, retroviral 
transgene integration into the genome did not lead to transformation or 
clonal expansion and did not favor integration near genes controlling cell 
growth. This data reveals that cell transformation due to genome 
modification induced insertional mutagenesis is not shared by all cell 
therapies involving gene modification. Susceptibility for transformation can 
depend on the transgene or cell type, with HSCs possibly presenting a higher 
risk (Newrzela et al. 2008, Schambach et al. 2013). 
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CARs are cellular synthetic receptors that are not found in nature. Two 
potential safety risks regarding the receptor structure may arise: The CAR 
itself can be recognized as foreign by the body’s natural immune cells 
(immunity against transferred CAR T cells) or the CAR, similarly to the 
affinity-enhanced TCR in TCR-engineered T cells, can recognize unintended 
structures (off-target immunity i.e. toxicity). However, compared to TCRs the 
target specificity of the antibodies is high and cross-reactivity less likely 
(Harris and Kranz 2016). So far, off-target reactivity has not been reported. 
The antibody segments in CARs are often derived from mouse Abs. 
Usually both heavy and light chain single-chain variable fragments (scFv) 
from the murine antibody are used (Dotti et al. 2014). Mouse-derived CARs, 
as well as TCRs, are able to induce the production of human anti-mouse 
antibodies (HAMA, (Lamers et al. 2006, Till et al. 2008, Davis et al. 2010)). 
These IgG class antibodies have not caused harm in patients. Instead, repeat 
dosing of mesothelin-targeted CAR T cells induced IgE HAMA generation 
and caused anaphylaxis and death in one case (Maus et al. 2013). On-target 
off-tumor reactions were anticipated due to mesothelin expression on normal 
tissues and therefore transient CAR expression was used as a safety 
procedure. Repeated dosing of CAR T cells was employed in order to prolong 
the treatment time. Mesothelin targeting was shown to be safe but repeated 
dosing of cells bearing mouse-derived components is now considered to be a 
potential safety concern. Murine-derived scFv domains in CARs can be 
humanized, which may also improve clinical efficacy hindered by HAMAs 
(Lamers et al. 2006, Davis et al. 2010) or cell-mediated immunity (Lamers et 
al. 2006, Turtle et al. 2016a, Turtle et al. 2016b). 
Since only a few tumor Ags are selectively expressed on malignant cells, 
on-target off-tumor toxicity is a main concern when developing CARs against 
new targets. Although CARs do not harness CD3 receptor complex signaling 
in its entirety, they are effective molecules requiring only ~50 target 
molecules per target cell to react (Maus et al. 2014). TCRs can respond 
against only 1-10 target Ags. Therefore, a very low level of Ag expression in 
normal tissues can be sufficient for the response activation: Carbonic 
anhydrase IX expression in the biliary tract triggered CAR-induced hepatitis 
in patients treated for renal cell carcinoma (Lamers et al. 2006) and ERBB2 
expression on lung epithelial cells led to the death of a patient treated for 
advanced colon cancer (Morgan et al. 2010). ERBB2 (also known as HER2) 
targeted immunotherapy using exactly the same regulatory-approved 
monoclonal antibody, trastuzumab, as well as utilizing CAR T cells with 
another scFv (Ahmed et al. 2015) has been safe. The most likely explanation 
for the unfortunate death was the huge cell dose given (1010, typical adult 
CAR T-cell dosing <5x108 corresponding to <5x106/kg, (Jackson et al. 2016, 
Turtle et al. 2016c)), which resulted in massive CAR T-cell infiltration into 
the lungs in 15 minutes. 
In summary, the complexity of CAR T-cell therapy may carry risks and 
clinical application must be approached with caution. 
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1.2.3.2 Clinical efficacy 
Clinical efficacy with first generation (1G) CARs, which only carried the CD3? 
signaling domain, was modest. Mimicking nature, the addition of a signaling 
domain from the CD28 T-cell cosignaling receptor into the CAR improved 
the efficiency (Figure 5). These second generation (2G) CAR T cells expand 
better in vivo after transfusion and exhibit longer persistence (Savoldo et al. 
2011). CARs with signaling domains from other cosignaling receptors, such 
as 41BB, OX40, and ICOS, have also been developed. ICOS signaling in CAR 
T cells favored a Th17 type response (Guedan et al. 2014). Furthermore, third 
generation (3G) CARs containing the CD3? domain and two cosignaling 
domains, most often CD28 and 41BB, are used. Comparisons between 
different cosignaling domains in 2G CARs (Milone et al. 2009, Frigault et al. 
2015, Kawalekar et al. 2016) or between 2G and 3G CARs (Milone et al. 
2009, Karlsson et al. 2015) have shown some functional differences but their 
impact on clinical performance is not known. 
Data for clinical efficacy of CAR T cells in solid cancers is still limited 
although dozens of trials are under way (n=60, www.clinicaltrials.gov). The 
results that are available have evoked cautious optimism (Jackson et al. 
2016): GD2-CAR for neuroblastoma (Louis et al. 2011), PSMA-CAR for 
prostate cancer, mesothelin-CAR for malignant pleural mesothelioma (Maus 
et al. 2013, Beatty et al. 2014), CEA-CAR for adenocarcinoma liver 
metastases, HER2-CAR for glioblastoma (Ahmed et al. 2015), and IL-13-CAR 
for glioma (Brown et al. 2015). Strategies for increasing the clinical efficacy 
include the local administration of CAR T cells, bigger cell doses, and the 
breaking down of the immunosuppressive tumor microenvironment. 
1.2.3.3 Clinical use of CD19-targeted CAR T cells 
Hematologic malignancies offer a feasible target for novel immunotherapies 
for two reasons. First, the tumor-induced immunosuppressive 
microenvironment is not as big an obstacle as in solid tumors. Second, 
hematologic cell types have lineage specific surface markers and thus the on-
target off-tumor toxicities are more predictable. Indeed, the biggest 
breakthrough in the field of advanced cell therapy has been the CD19-
targeted CAR T cells against refractory B-cell malignancies. Phase I and II 
trials conducted in different centers consistently produce astonishing 
complete response rates between 51 to 93%  in acute lymphoblastic leukemia 
(ALL, altogether 165 patients in four centers, (Davila et al. 2014, Maude et al. 
2014, Lee et al. 2015, Turtle et al. 2016a, Turtle et al. 2016c)) along with 
encouraging responses in chronic lymphocytic leukemia (CLL, altogether 31 
patients in four centers with overall response rates up to 89%, (Brentjens et 
al. 2011, Kochenderfer et al. 2012, Turtle et al. 2016c)) and non-Hodgkin 
lymphoma (NHL, altogether 69 patients in four centers with overall response 
rates up to 68%, (Savoldo et al. 2011, Kochenderfer et al. 2015, Turtle et al. 
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2016b, Turtle et al. 2016c)). A multicenter phase II trial for pediatric ALL is 
ongoing and shows consistent clinical results (Maude et al. 2016). Currently, 
there are 121 ongoing CAR T-cell trials for lymphoma or leukemia worldwide 
(www.clinicaltrial.gov). 
Adverse effects for CD19-targeted CAR T cells can be significant but in 
great majority of cases manageable (Turtle et al. 2016c). The expected on-
target off-tumor consequence is the depletion of normal B cells. This B cell 
aplasia can be long-term depending on the persistence of transferred CAR T 
cells. It predisposes the patient to infections through the lack of antibodies 
but can be managed with monthly Ig infusions. Two other toxic effects, 
cytokine release syndrome (CRS) and neurological toxicity, are encountered 
in all clinical trials that show efficacy and may be related to the tumor 
burden. CRS and neurotoxicity are also experienced with blinatumomab, a 
bispecific anti-CD3–anti-CD19 mAb that activates endogenous T cells while 
simultaneously binding to target B cells. Blinatumomab can also be used for 
leukemia. CRS and neurologic effects are usually transient but may require 
intensive care. The pathophysiology of neurotoxicity is not understood. On 
the other hand, CRS is induced by cytokines, particularly IL-6, which are 
released in response to immunological danger signals originating from 
damaged tumor cells after CAR T-cell attack. These toxicities can be treated 
with an anti-IL6R mAb, tocilizumab. Corticosteroids, which inhibit CAR T 
cell function as well, are used in the most severe cases. Still, two patients 
treated for lymphoma have died of severe CRS and neurotoxicity (Turtle et al. 
2016b). In this trial, cell dose at 2x106/kg was determined as the maximum 
dose tolerated, with 20x106/kg being excessively toxic. In CD19-targeted CAR 
therapy, only one more contingently CAR T-cell-related but undecipherable 
death has occurred (Kochenderfer et al. 2015). 
Hope of a permanent cure for formerly refractory cancer with CAR T cells 
has arisen from the long-lasting remission attained in some of the patients 
treated against CD19+ malignancies. In one clinical center, the rate of 
disease-free survival at 1 year among the complete responders in ALL was 
44% (Maude et al. 2014, Turtle et al. 2016c). Two thirds of the relapses were 
due to CD19- escape mutants. However, about dozen patients with ALL, CLL, 
and NHL have now remained in remission for several years (Maude et al. 
2014, Turtle et al. 2016b, Turtle et al. 2016c) indicating that a cure may be 
within reach. 
1.2.3.4 CAR T-cell generation 
CAR T cell production follows the steps that are also used for TCR-
engineered T cells: blood T cells activated with anti-CD3 Ab are transduced, 
usually, with a viral vector carrying the CAR sequence and expanded for one 
to two weeks. Again, the direct mechanism for tumor cell elimination is 
achieved by CD8+ T cell cytotoxicity, even though a mix of both CD4+ and 
CD8+ T cells is generated. 
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A major drawback hampering the wider use of CAR T-cell therapy results 
from the normal antibody function: only structures that are exposed outside 
the cell membrane can be targeted. Unfortunately, many of the useful tumor 
Ags are intracellular. A novel approach to circumvent the need for cell 
surface expression is to use scFvs derived from antibodies that recognize 
tumor Ag-derived peptides upon HLA presentation (Liu et al. 2016). 
However, Ag presentation by tumor cells is needed and thus one of the 
greatest advantages of CARs is lost. 
Genetic engineering has introduced further options for improving T-cell 
therapies and several discoveries are currently being tested in the clinic as 
well (reviewed in (Jackson et al. 2016)). Both efficacy and safety are in focus, 
and CAR T cells bearing, for example, additional synthetic receptors for 
chemokines to improve homing, or engineered to produce cytokines that 
activate bystander immunity (IL-12) are being developed, in addition to 
safety switches. Dual-specific CAR T cells are tested for increased specificity 
and to decrease the risk for escape mutants. 
The factors that determine clinical efficacy can depend on the treatment 
protocol or the T-cell product and once known could be applied more 
comprehensively. 
1.3 IN VITRO T-CELL EXPANSION 
T cell numbers that can safely be collected from tumor biopsies or blood are 
considered insufficient for clinical efficacy, with pathogen-specific T cells 
being a prominent exception. Multiplication of the cell number, i.e. 
expansion, is thus a common part of most adoptive T-cell modalities. In vitro 
T-cell expansion can also provide other benefits, such as improving the 
purity of desired cell type or functionality due to cell activation. Conversely, 
in case of nonphysiologic cell manipulation, expansion evokes safety issues. 
T-cell biology is the foundation for all T-cell expansion technologies, with 
cell culturing techniques providing the framework. In vivo, T-cell 
proliferation takes place during an immune reaction. Tregs, too, proliferate 
upon immune response but later in order to limit the activation (Tang and 
Bluestone 2013). Therefore, T-cell expansion in vitro, for both conventional 
and regulatory T cells, is based on T-cell activation. All three physiological 
signaling events, TCR-CD3 mediated Ag-recognition (first signal), cosignal 
through CD28 (second signal), and the IL-2 -delivered signal (third signal), 
are typically included in the clonal expansion-based in vitro proliferation. 
 The technical solutions are either based on soluble anti-CD3 antibodies 
with or without anti-CD28 or the use of these antibodies immobilized on 
beads (Maus et al. 2014). Formerly, APCs were used but, in addition to the 
improved control and safety, CD28-specific Abs bypass the possible 
interference of CTLA4 engagement that would result in T-cell inhibition. 
However, cord blood Tregs were recently expanded with artificial APCs, a 
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transduced cell line providing the CD3 signal via anti-CD3 Ab and the 
cosignal via CD86 (McKenna et al. 2017). Cellular expansion was more 
efficient compared to beads exploiting solely CD28 binding. Perhaps cells 
were providing stronger CD28 stimulus, which is known to be required for in 
vitro expansion of Tregs (Hombach et al. 2007). APCs are also utilized in the 
production of Ag-specific Tregs in order to enrich the desired T-cell clones 
(Putnam et al. 2013). In case of the oligo-clonal alloreactive Tregs, no 
substitute for APCs exists. However, if the specific autoantigen driving the 
autoimmune disorder was known, APC-based methods could be replaced 
either with HLA-tetramer systems (Neudorfer et al. 2007) or even with 
genetic engineering (Noyan et al. 2016). Traditionally, in the REP phase of 
TIL production, soluble anti-CD3 antibody together with autologous feeder 
cells are used (Dudley and Rosenberg 2003). Recently, anti-CD3/CD28 
beads have been introduced (Baldan et al. 2015). 
As mentioned before, there has not been a firm consensus on the 
exploitation of CD28 in effector T-cell expansion. Several facts in basic 
biology point to benefits received through cosignaling. Naïve T cells, the most 
abundant subset in methods starting from blood, cannot be activated without 
CD28. The lack of this non-redundant cosignal drives them to anergy 
(Schwartz 1990) or can lead to Treg differentiation (Wraith 2016). Also, the 
full activation of Ag-experienced T cells benefits from CD28 signaling. 
Finally, CD28 stimulation maintains telomere length (Weng et al. 1996). 
Combined, these advantageous effects produce higher cell numbers for 
treatment, increase potency, and prolong performance time. 
The anergic state of Treg cells complicates their expansion. In addition to 
intense CD28 signaling, high IL-2 concentration helps to break the anergy 
(Hoffmann et al. 2004, Hombach et al. 2007, Putnam et al. 2009). In 
addition, IL-2 is needed for the survival of Tregs and the maintenance of 
their function (Malek and Bayer 2004, Nelson 2004). 
IL-2 is called the T-cell growth factor because of its central function in 
clonal expansion. Thus, IL-2 supplementation is used extensively for in vitro 
T-cell expansion. However, ample proliferation eventually leads to lower 
potency owing to expression of inhibitory molecules (e.g. CTLA4, PD-1), cell 
exhaustion, or senescence (Shen et al. 2007). Continuous activating signals 
may cause activation-induced cell death. Furthermore, IL-2 itself drives T 
cells toward effector differentiation (D'Souza and Lefrancois 2003, Yu et al. 
2003), with both IL-2 signaling strength and duration affecting CD8+ 
memory (Boyman and Sprent 2012). Excessive effector T-cell content at the 
expense of memory cells is an undesired outcome in T-cell products intended 
for treatment of cancer. Clinical results have indicated that T-cell persistence 
is needed (Robbins et al. 2004, Maude et al. 2014) and that it depends at 
least in part on immunological memory (Powell et al. 2005, Kalos et al. 2011, 
Louis et al. 2011). A growing body of evidence from preclinical animal models 
supports the utilization of less-differentiated early memory T cells with 
greater proliferation capacity and survival after infusion (TSCM, TCM), instead 
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of cells that bear the apparent cytotoxic function (TEM, TEff, (Gattinoni et al. 
2005, Gattinoni et al. 2011, Barrett et al. 2014a, Sommermeyer et al. 2016)). 
Because T-cell proliferation and effector/memory differentiation are 
inherently coupled upon clonal expansion (Crompton et al. 2014), novel 
methods founded on homeostatic proliferation are currently being tested 
(Gattinoni et al. 2005, Cieri et al. 2013, Xu et al. 2014, Gomez-Eerland et al. 
2014, Gargett and Brown 2015, Singh et al. 2016). In vivo, homeostatic 
proliferation affects naïve and memory T cells in lymphopenic conditions 
where the level of lymphocytes is reduced and is responsible for the life-long 
low-level replication of these cells (Jameson 2002, Rochman et al. 2009). In 
these situations, the proliferative signal is mainly delivered by IL-7, but IL-15 
is used in vitro to enhance the effect. Expression of the IL-7 receptor, CD127, 
is confined to naïve and memory T cells, thus being nearly absent on 
activated T cells (Rochman et al. 2009) and Tregs (Seddiki et al. 2006, Liu et 
al. 2006). Proliferation in response to IL-7 causes the cell to retain its initial 
differentiation phenotype. Regarding the homeostasis of naïve cells, weak 
TCR signaling in the form of self-peptide recognition and sense of T-cell 
‘space’ (lack of T cells) is required in addition to cytokines. Experiences of 
using these cytokines for in vitro T-cell expansion instead of IL-2 are mostly 
restricted to CD8+ T cells (Cieri et al. 2013, Xu et al. 2014, Gomez-Eerland et 
al. 2014, Gargett and Brown 2015, Sabatino et al. 2016). 
Cell composition in the starting material has a critical impact on the cell 
subset composition of the final product. Cancer treatment with 
chemotherapy alters the differentiation state of blood T cells towards effector 
phenotypes (Singh et al. 2016, Sommermeyer et al. 2016). The presence of 
naïve or TSCM cells is essential for the generation of T cells that are capable of 
persisting in vivo and to provide improved clinical performance (Singh et al. 
2016). In vitro expansion of less-differentiated T cells is, therefore, also 
approached by selecting more primitive starting populations for the 
expansion (Sommermeyer et al. 2016) or by interrupting the effector 
differentiation using signaling inhibitors (Sabatino et al. 2016). 
All forms of in vitro T-cell expansion alter the characteristics of the cells. 
Therefore, both cell quality and safety need to be controlled. Uncontrolled 
proliferation could lead to genetic instability and malignant transformation. 
Also, expansion can influence the cellular plasticity compromising the cell 
identity and function. 
1.4 CELL THERAPY REGULATION AND CURRENT 
STATUS IN FINLAND 
Authority regulations apply to all tissue and cell therapeutics, as well as to 
blood products for transfusion medicine. Two ex vivo processing categories, 
minimal vs. substantial manipulation of the cells, classify T cells respectively, 
either as tissue products (Tissue Act 101/2001 on the Medical Use of Human 
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Organs and Tissues) or as advanced therapy medicinal products (ATMP, 
Article 17 of Regulation (EC) No 1394/2007). In practice, only pathogen-
specific T cells that are produced with the reversible HLA-tetramer binding 
method (Neudorfer et al. 2007) and Tregs isolated utilizing the same 
technique and used without further expansion are regarded as tissue 
products. In the European Union, ATMPs need marketing authorization 
from the European Medicine Agency through a clinical trial demonstrating 
the safety and efficacy. Conducting a clinical trial also requires regulatory 
approval.  As an option for individualized treatment of individual patients 
with ATMPs, a national production authorization, so-called hospital 
exemption, can be requested from the competent national authority 
controlling the quality and safety (in Finland from Fimea; Määräys 5/2014 
19.12.2014 Dnro 002646/00.01.00/2014). 
ATMPs are medicines, and the production must follow good 
manufacturing practice (GMP). GMP is a comprehensive quality system 
implemented to ensure that the patient is not placed in risk, and it covers all 
aspects of drug manufacturing (European Guide to Good Manufacturing 
Practice, Eudralex, http://ec.europa.eu/health/documents/eudralex/vol-
4_en). To meet current GMP requirements, cell production needs to be 
conducted in clean rooms or in closed systems for ensuring sterility, with 
traceability that covers the starting material (tissue, blood) and raw materials 
used in the production method (e.g. serum or other growth factors) as well as 
the final product. Quality control, release testing, and quality assurance need 
to be in place. Methods and instruments for the production and quality 
control must be validated, every procedure instructed, and all personnel 
appropriately trained. Documentation for each relevant step during and 
related to the manufacturing process (e.g. training of cleaning personnel) is 
mandatory. 
Overall, eight ATMPs have been approved in the European Union 
(http://www.ema.europa.eu/docs/en_GB/document_library/Committee_m
eeting_report/2017/01/WC500219367.pdf); the first, ChondroCelect® 
(TiGenix), for cartilage repair in 2009. By 2016, 14 Finnish patients have 
received this autologous cellular medicine (reference Finnish Red Cross 
Blood Service). Three approved medicines have been withdrawn from the 
market for business reasons (ChondroCelect®, MACI® and Provenge®). 
Zalmoxis® (MolMedSpA), the only T cell-based product with marketing 
authorization was approved in 2016. It can be used to improve engraftment 
and immune reconstitution in HSC transplantation. These donor-derived T 
cells are genetically modified by retroviral transduction to express two 
transgenes, a truncated form of the human Low-affinity nerve growth factor 
receptor LNGFR and the herpes simplex I virus thymidine kinase (HSV-TK 
Mut2). T-cell treatment can lead to acute GVHD, which can be abolished by a 
HSV-TKMut2 -activated pharmaceutical that kills the modified T cells 
causing the adverse effect. Zalmoxis® increased the patient one-year overall 




In Finland, three advanced cell therapy trials were recorded before 2016 
(www.fimea.fi/valvonta/kliiniset_laaketutkimukset/tilastotietoa_kliinisista_
laaketutkimuksista), one in 2011 and two in 2015. For comparison, more 
than 700 clinical trials were registered globally in the field of cell and gene 
therapy and regenerative medicine in 2016 
(http://alliancerm.org/page/clinical-trials-products). Tregs, TILs, virus-
specific T cells, and CAR T cells are studied in European clinical trials (n=3, 
41, 9, and 11, respectively, www.clinicaltrials.gov), however not yet in 
Finland. Instead, the Finnish Red Cross Blood Service is allowed by the 
special permission by the competent authority to import virus-specific T cells 
from Germany. An urgent cell production order for individual Finnish HSC 
transplantation patients is coordinated through the Finnish Stem Cell 
Registry. This special procedure has been conducted for eight severely ill 
patients between years 2014 and 2017. 
Two cell therapy products are produced under the national production 
authorization (hospital exemption) in Finland. A tissue-engineered product 
consisting of autologous adipose stem cells is used for the reconstruction of 
large bone defects (BioMediTech, (Wolff et al. 2013)). Refractory GVHD can 
be treated with immunosuppressive allogeneic mesenchymal stromal cells 
(Finnish Red Cross Blood Service, (Salmenniemi et al. 2016)). 
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2 AIMS OF THE STUDY 
The studies of the present thesis aimed at creating sufficient expert 
knowledge for the development of T-cell-based cellular therapies at the 
Finnish Red Cross Blood Service. An objective was to develop therapeutically 
meaningful ways to expand and activate T cells and to evaluate their 
functionality. Also, characterization of genetic variation regulating activation 
of T cells can be used for the development of personalized medicine. 
 
Specific aims for each publication were: 
 
 
I to reveal how different in vitro cell expansion conditions affect 
the composition and therapeutic potency of T-cell products. In addition, this 
knowledge is used to develop an effective T-cell expansion protocol that can 
be applied to the clinical production of CAR T cells. 
 
II to determine the relevance of the CTLA4 receptor and its soluble 
isoform to the potency of Tregs in inhibiting the T-cell response. Both freshly 
isolated and in vitro expanded Tregs were studied. 
 
III to evaluate whether genetic polymorphisms in T-cell cosignaling 
receptor genes affect the expression of CTLA4. 
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3 MATERIALS AND METHODS 
3.1 ETHICS AND HUMAN MATERIAL 
This study was approved by the institutional review boards of the Finnish 
Red Cross Blood Service (I-III) and the Hospital District of Helsinki and 
Uusimaa (I and III). Informed consent was obtained from the involved 
participants when applicable (I and III). Human T cells (I) and Tregs (II) 
were expanded in vitro, starting from buffy coats that were processed from 
the donated blood of healthy blood donors (I and II). Also, whole blood 
samples from two leukemia patients were used for T-cell expansion (I). Study 
subjects, who voluntarily participated in the functional genetic studies (III) 
were healthy adults. 
3.2 METHODS 
The methods that were used in the studies are described in the original 
publications (I-III) or, regarding the additional unpublished data, are briefly 
described here.  All the methods are listed in Table 4. T cell phenotyping was 
based on antigens and their expression patterns that are shown in Table 5. 
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Table 4 The methods used in the thesis. 
Procedure Method Publication 
Cell isolation 
- MNC 
- T cells (CD3+) 
- Treg, Th 
- CD4+ T cells 
 
- density-gradient centrifugation 
- positive selection with magnetic beads 
- FACS sorting 







- B-cell lines 
- primary T cells 





Genetic modification lentiviral transduction I 
Phenotyping/Ag detection flow cytometry 
- cell surface 
- intracellular 
I, II, III 
Cell functionality tests 
- cytotoxicity# 
 
- cytokine secretion# 
- proliferation# 
- immunosuppression# 
- T-cell activation 
 
- CTLA4 blocking# 
 
- calcein release assay, 
degranulation test 
- cytometric bead array (CBA) 
- CFSE dilution assay 
- CFSE dilution assay 
- polyclonal activation 
Ag specific activation via CAR 







I, II, III 
I 
* 
RNA extraction RNA isolation kit II, III 
Analysis of mRNA qRT-PCR II, III 
DNA extraction DNA isolation kit III 
Genotyping - SNaPshot (minisequencing) 
- RFLP 
- SSP (allele specific) 
III 
# Co-cultures of different cell types 
* Unpublished data 
CFSE = carboxyfluorescein diacetate N-succinimidyl ester, MNC = mononuclear cells, RFLP = 
restriction fragment length polymorphism. SSP = sequence-specific primers. qRT-PCR = quantitative 
reverse transcriptase-polymerase chain reaction. 
CTLA4 BLOCKING EXPERIMENTS 
To study the functional significance of CTLA4 in Tregs before (denoted as 
fresh Tregs herein) and after expansion, a modification of the 
immunosuppression test measuring responder cell proliferation (II) was 
used. CFSE-stained MNCs were stimulated for 5 days using a soluble anti-
CD3 antibody (clone Hit3a from BioLegend, USA) at 0.5 μg/mL to induce a 
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suboptimal proliferative response (~50% of the responder cells proliferating 
at the end of the assay). Proliferation was measured with flow cytometry. 
MNCs were co-cultured with Tregs using different cell ratios (1:1, 1:0.5, and 
1:0.2 responders to Tregs). A blocking anti-CTLA4 antibody (clone BNI3 
from BD Pharmingen, USA) was used at 10 μg/mL. Suppressive function was 
compared to positive proliferation controls that also included anti-CTLA4 
antibody (MNC + anti-CD3 Ab + anti-CTLA4 Ab). Same amount of isotype 
matching control antibody with irrelevant specificity (mouse IgG2a, clone 
eBM2a from eBioscience, USA) alone inhibited the proliferation of responder 
cells. This inhibition was even stronger than Treg-mediated inhibition. 
However, the anti-CTLA4 antibody did not have a similar effect on responder 
cells but rather slightly increased their proliferation. Also, in certain co-
cultures of responder and Treg cells the presence of anti-CTLA4 antibody did 
not alter the responder cell proliferation (Table 8). Based on this data, the 
effect of the isotype control was considered unspecific and irrelevant 
regarding CTLA4 blocking experiments, and it was not used for data analysis. 
The effect of CTLA4 blocking was compared to identical co-cultures without 
any antibody. Expanded Tregs were tested in flat-bottom culture wells. For 
fresh Tregs U-bottom wells, which allow cell contact also for small cell 
numbers and thus more uniform testing conditions, were used. 
 
Table 5 Antigens and their expression patterns used for phenotyping. Sequential 
differences in expression between T-cell differentiation subtypes are shown 
using underlining. TSCM, TSCM-like, and TCM cells represent less-differentiated, early 
memory T cells. 
 Antigens Publication 
T cells CD3+ I, II 
cytotoxic T cells CD3+ CD8+ I 
helper T cells CD3+/CD14- CD4+ I,II,III 
T-cell differentiation status:  I 
Naïve CD95- CD45RO- CD45RA+ CD27+  
TSCM CD95+ CD45RO- CD45RA+ CD27+  
TSCM-like CD95+ CD45RO+ CD45RA+ CD27+  
TCM CD95+ CD45RO+ CD45RA- CD27+  
TEM CD95+ CD45RO+ CD45RA- CD27-  
TEff CD95+ CD45RO+ CD45RA+ CD27-  
Tregs 
additional markers 
CD4+ CD25+ CD127 low/- 
Foxp3, CTLA4 
II 
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Table 6 Genotyped T-cell cosignaling receptor gene polymorphisms (III). 
Polymorphism reference cluster ID* Genotyping method 
CTLA4-318C/T rs5742909 RFLP 
CTLA4+49A/G rs231775 RFLP 
CT60G/A rs3087243 RFLP 
ICOS IVS1+173T/C rs10932029 SNaPshot 
ICOS c.602A/C rs10183087 RFLP 
ICOS c.1624C/T rs10932037 SNaPshot 
ICOS c.2373G/C rs4675379 SSP 
* http://www.ncbi.nlm.nih.gov/projects/SNP/ 
3.3 STATISTICAL ANALYSES 
The differences between T-cell expansion conditions were analyzed with 
Mann-Whitney test (I), between fresh and in vitro expanded Tregs using 
paired t-test (II), and between genotypes by Kruskal-Wallis test (III). 
Correlations were analyzed using Spearman’s correlation (II). The 
dependence of cytotoxicity on effector to target cell ratios and IL-2 levels was 
tested using a linear modelling analysis (I). Differences were considered 
statistically significant when two-sided P values were <0.05. Analyses were 
performed using GraphPad Prism (version 6.07, I and II), R for the linear 
modelling analysis (version 3.3.1, I), StatsDirect (version 2.7.7, II), or SPSS 
software (version 14.0, III). 
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4 RESULTS 
The results presented here are a summary focusing on the most significant 
findings in each study with respect to the context and topic of the thesis. 
More detailed results are reported in the original publications. 
4.1 T cells cultured in a low IL-2 concentration are 
functionally potent with early memory phenotype (I) 
Efficacy of T-cell therapy for cancer and infections, including the CAR T cells, 
can be improved using cell products containing less-differentiated early 
memory T cells. To this end, systematic studies were conducted on the effects 
of IL-2, “the T-cell growth factor”, and the in vitro expansion time on the 
balance between T-cell numbers and cell composition. Blood-derived T cells 
(11 donors: 9 healthy and 2 leukemia patients) were expanded using anti-
CD3/CD28 beads and supplemented with varying concentrations of IL-2 
ranging from 0 to 300 IU/mL. The cell phenotype was analyzed on the tenth 
and twentieth days of the expansion. The growth kinetics was monitored 




Figure 6 Memory T-cell subsets after 10-day in vitro expansion under varying IL-2 conditions 
(0 IU/mL n=5, 5 IU/mL n=6, 20 IU/mL n=11, 100 and 300 IU/mL n=10). Means and 
95% confidence intervals are depicted. Transparent data points represent patient 
samples and colored the samples from the healthy donors. Mann-Whitney test was 





Figure 7 a) Change in TSCM during in vitro T-cell expansion (n=6). Memory status was 
phenotyped on days ten and twenty of the expansion. Representative data from 
expansions with 20 IU/mL IL-2 is shown. b) Slower proliferation until the 6th day of 
the in vitro expansion was linked to the lack of TSCM on day 10 (n=6 for d10 TSCM 
negative and n=5 for d10 TSCM positive cultures, P=0.03). Expansion kinetics was 
studied in expansions with 20 IU/mL IL-2. Mann-Whitney test was used to calculate 
statistical significance between expansions that were either positive or negative for 
TSCM on day 10. The transparent symbols represent expansions that were negative 
for TSCM on day ten. 
After ten days of expansion, cultures supplemented with a lower 
concentration of IL-2 had a higher proportion of less-differentiated TCM and, 
on the other hand, a lower relative amount of effector T cells (Figure 6). The 
overall content of early memory T cells (TSCM, TSCM-like, and TCM) was high but 
decreased along with the increasing levels of IL-2: the cultures without 
exogenous IL-2 had an average of 88% of early memory T cells and the 
cultures supplemented with 300 IU/mL IL-2 still had 61% (P=0.03). Naïve T 
cells were not detected after expansion. Between 20 to 300 IU/mL IL-2, the 
memory T-cell generation from the leukemic donors was in a similar way 
dependent on the exogenous IL-2 as from the healthy donors (Figure 6). The 
two patient samples were not studied in the two lowest IL-2 concentrations. 
Patient material yielded products with smaller proportions of early memory 
T cells and higher levels of more differentiated T cells (TEM and TEff). At day 
20, the proportion of early memory T cells had decreased to about a half of 
the day 10 levels (I, Figure 5). 
Half of the expansions were entirely deficient in TSCMs at the 10-day time 
point (Figure 6, 55% TSCM negative, n=11). All concurrent cultures from the 
same cell material were negative for TSCMs indicating that the lack was not IL-
2 dependent. Further expansion until day 20 induced TSCM in those cultures 
that previously were negative but decreased TSCM levels in other cultures 
(n=6, Figure 7a). Poor expansion during the first week of in vitro expansion 
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was associated with the lack of TSCMs on day 10 (n=11, Figure 7b). A three-fold 
difference in the cumulative fold expansion before the sixth expansion day 
was detected, corresponding to  4- and 13-fold mean expansion for 
expansions lacking TSCMs or positive for TSCMs, respectively, on day 10 (using 
20 IU/mL IL-2, P=0.03). 
The T-cell cultures consisted of CD4+ and CD8+ T cells. A longer 
expansion time yielded products with a prevalence of CD8+ cells: there was a 
2- to 4-fold decrease in CD4+ cells from day 10 to day 20 (e.g. from 43% to 
18% using 20 IU/mL IL-2, d10 n=11 and d20 n=6, P=0.03; I, Figure 6). 
As expected, when less exogenous IL-2 was used for the expansion, the 
resulting cell numbers were lower (Table 7; I, Figure 4). 100 IU/mL IL-2, the 
current standard used in CAR T-cell production, as well as 300 IU/mL IL-2 
produced exponential proliferation kinetics beyond twenty days. The cell 
expansion was modest with low IL-2 supplementation (~10-fold at day 10 
with 0-5 IU/mL). 
In vitro functionality of the expanded T cells was studied after 10-day 
expansion using CAR T cells as an example. All CD19-targeted CAR T-cell 
expansion products had multiple functions against their targets, CD19+ 
leukemia cell lines,  regardless of which IL-2 concentration was used for 
expansion (n=3; I, Figure 7C-F). The T cells proliferated, secreted IL-2 and 
IFN?, and showed potent cytotoxicity in response to exposure to target cells. 
When higher IL-2 levels were used during T-cell expansion, the killing 
activity increased (n=4, 0 vs. 100 IU/mL IL-2 P<0.0001). This increase is in 
agreement with the results showing increased effector T-cell generation. 
 













on day 20 
mean (min-max) 
No IL-2 11 (4-18) 10 - 
5 IU/mL IL-2 12 (3-21) 10-13 - 
20 IU/mL IL-2 39 (4-100) <14 140 (22-560) 
100 IU/mL IL-2 60 (3-150) >20 590 (1 200-4 500) 




4.2 Treg expansion decreases alternative CTLA4 
splicing and yields more potent CTLA4 receptor 
bearing cells (II) 
CTLA4 is significant for the function of regulatory T cells but the relevance of 
its soluble isoform, sCTLA4, is not clear. Expression of CTLA4 isoforms was 
studied before and during in vitro Treg expansion, along with the 
immunosuppressive function of the cells. Current reagents cannot 
distinguish between the CTLA4 receptor and sCTLA4 proteins. Also, the 
CTLA4 receptor mainly has an intracellular localization due to its tightly 
controlled surface expression. Therefore the mRNA levels of CTLA4 receptor 
and sCTLA4 were measured. Tregs were isolated from the blood of healthy 
donors with FACS sorting (denoted as fresh Tregs herein). Some of the cells 
were directly analyzed, while the remainder were expanded using anti-
CD3/CD28 beads with a very high concentration of IL-2 (1 000 IU/mL). 
High supplemental IL-2 was used to break the physiological Treg anergy. 





Figure 8 a) mRNA levels of the soluble and full-length CTLA4 isoforms (sCTLA4 and 
flCTLA4, respectively) in fresh and Tregs expanded for 14 days. flCTLA4 encodes 
the CTLA4 receptor, sCTLA4 being its differently spliced variant. Mean ± standard 
deviations are shown, n=7. A paired t-test was used to calculate statistical 
significance (*P=0.0002).  b) Expansion kinetics of Tregs that were expanded using 







In vitro expansion decreased the expression of sCTLA4 (Figure 8a). 
However, shortly after the CD3/CD28-mediated activation, at the three-hour 
time point, the sCTLA4 expression was in fact induced in comparison to 
unstimulated cells (II, Figure 4). In contrast, the mRNA level for the CTLA4 
receptor, full-length CTLA4 (flCTLA4), increased as a result of expansion 
(P=0.01). An 11-fold mean increase in the intracellular, total CTLA4 protein 
content was achieved with the 2-week expansion of Tregs (range 5-17, n=7; 
II, Figure 1A). The data includes both CTLA4 receptor and sCTLA4. The 
expansion kinetics of Tregs was biphasic (Figure 8b): the cell proliferation 
was modest during the first week (on average eightfold) but subsequent re-
stimulation provided a 210-fold mean expansion (range 50-350, n=7). 
The immunosuppressive potential of fresh and expanded Tregs was 
compared in a T-cell proliferation assay (Table 8). Expanded Tregs were to 
some extent more immunosuppressive than Tregs that were tested directly 
after isolation (with 1:1 responder cell to Treg ratio, P=0.27). The strength of 
the T-cell activation manifested either as a suboptimal or optimal 
proliferative response (25-60% and 75-100% of responder cells proliferating 
after 4-day co-culture) did not influence the Treg-mediated inhibition (II, 
Figure 2). 
 
Table 8 Immunosuppressive potential of fresh and expanded Tregs. The inhibition of 
responder cell proliferation was tested on suboptimal response (25-60% of 
responder cells proliferating) after 4 day co-culture (n=3, except n=7 for fresh 
Tregs).Immobilized anti-CD3 antibody (clone UCHT1) was used for the 
responder cell activation. The effect of the total CTLA4 blocking (both CTLA4 
receptor and sCTLA4 together) was studied in 5-day cultures (n=3).In the 
blocking studies, a soluble anti-CD3 antibody (clone Hit3a) was used. Studies 
were conducted in U-bottom culture wells, except the blocking studies with 
expanded cells which were done in flat-bottom wells. Percentages for Treg 
suppression were calculated comparing the co-cultures with positive proliferation 
controls (similar cultures including only stimulated responder cells).Detected 
differences were tested by nonparametric tests (Mann-Whitney or Wilcoxon 
matched-pairs signed rank test) and were not statistically significant. Mean ± 
standard deviations are shown. 
 suppression % 
responders:Tregs fresh expanded 







1:1 63 ±16 59 ±22 83 ±21 83 ±18 
1:0.5 60 ±25 44 ±27 59 ±17 56 ±19 




The CTLA4 blocking (both CTLA4 receptor and sCTLA4) slightly 
inhibited the immunosuppressive function of fresh Tregs but only with high 
responder cell to Treg ratios (1:0.5 and 1:0.2, Table 8). This weak blocking 
effect did not reach statistical significance (P=0.25). With these cell ratios, 
fresh Tregs were equally potent as suppressors as the expanded cells. 
However, the testing conditions were not totally free from experimental 
differences (U- vs. flat-bottom culture wells were used respectively for fresh 
or expanded cells), thus leaving the significance of this data open. The 
correlation between the mRNA levels of CTLA4 isoforms and the level of 
Treg-mediated suppression points to a role for flCTLA4 in Treg 
immunosuppressive function (r = 0.93, n=7 including 5 fresh and 2 
expanded cell samples, P=0.007; II, Figure 5). Hence, CTLA4 mRNA levels 
may be utilized to predict the functional potency of Treg products. sCTLA4 
expression was negatively correlated with the inhibitory function (r = -0.57, 
P=0.2). The inhibiting function of expanded Tregs was not affected by 
CTLA4 blocking under testing conditions slightly different to those used for 
fresh cells (U- vs. flat-bottom culture wells were used respectively for fresh or 







4.3 Genetic variation in T-cell cosignaling receptor 
genes regulates the mRNA expression of CTLA4 in 
addition to alternative splicing (III) 
CTLA4 is a key regulator of T-cell response against tumors, mediating Treg 
function, and restraining autoimmunity. We studied how genetic variation in 
the CTLA4 gene region on chromosome 2, containing genes for CD28, 
CTLA4, ICOS, and PD-1, changes the expression of the full-length CTLA4 
receptor and its secreted sCTLA4 isoform. mRNA levels were measured in 
blood CD4+ T cells, including CD4+ Tregs, of 17 healthy volunteers before and 
during anti-CD3 and CD80 induced stimulation. 
Depending on a genetic polymorphism in the ICOS gene (IVS1+173T/C, 
rs10932029), both CTLA4 isoforms were expressed differently upon T-cell 
activation (Figure 9). Homozygous carriers of the T allele showed on average 
a two-fold increase in the expression of both flCTLA4 and sCTLA4 shortly 
after T-cell activation.  Without activation no difference was seen (data not 
shown). Regardless of genetic variation, T-cell activation mostly induced the 






Figure 9 T-cell activation-induced change in the mRNA expression of CTLA4 isoforms 
(sCTLA4 in (A) and flCTLA4 in (B)) in 17 healthy volunteers carrying either the TT 
or TC genotype in the IVS1+173 polymorphism (rs10932029) in ICOS gene. Means 
for each genotypic group are shown in the left panel where at 3h time point in A) 
n=7 for TT and n=8 for TC genotype and at 6h time point in B) TT n=6 and TC n=5. 
Statistical significance was analyzed using the Kruskal-Wallis test. Figures from 




In resting cells, the alternative splicing of CTLA4 varied according to 
another genetic variation located near the CTLA4 gene (CT60G/A, 
rs3087243). The mean sCTLA4 level was higher, 0.06, in 7 GG homozygotes 
compared to 0.11 in 10 persons carrying the A allele (9 GA + 1 AA, P=0.01, 
Figure 10). This genetic effect was only revealed in non-activated cells. 
Conflicting reports of the functional role of CT60G/A polymorphism has 
been published. Our data contradicts the reports by Atabani and Mayans 





Figure 10 The mRNA expression level of the soluble CTLA4 isoform (sCTLA4) in resting CD4+ 
T cells of 17 healthy volunteers (n=7 for CT60 GG and n=10 for other CT60 
genotypes (9 GA and 1 AA)). CT60 (rs3087243), an intragenic polymorphism, is 
located between the genes encoding CTLA4 and ICOS. Means for each group are 
shown. Statistical significance was analyzed using the Kruskal-Wallis test. Figure 




5.1 In vitro cell expansion in adoptive T-cell therapies (I 
& II) 
The effect of IL-2 on memory T-cell differentiation 
In this study, a simplified and lean in vitro expansion protocol was developed 
for the production of T cells with potent effector functions (I). By lowering 
the amount of supplemental IL-2 during the in vitro expansion, a higher 
proportion of less-differentiated memory T cells was generated. Cell products 
that have a substantial amount of early memory T cells are expected to 
perform clinically better due to improved in vivo survival, as denoted in 
cancer therapy (Robbins et al. 2004, Maude et al. 2014). 
The expansion method presented in this thesis is directly applicable for 
the production of CAR T cells and TCR-engineered T cells. Today, standard 
methods for CAR and TCR-engineered T-cell production utilize 100 or more 
IU/mL of IL-2 (Mock et al. 2016), which in this study generated a more 
unfavorable ratio between early memory T cells and effectors compared to T 
cells expanded without or with only a low level of supplemental IL-2. 
Therapeutic approaches based on tumor infiltrating T cells, TILs, would also 
benefit from the maintenance of  cell longevity, as the starting material in 
itself represents Ag-primed and even exhausted cells. Current TIL protocols 
use as high a level of IL-2 as 3 000-6 000 IU/mL for several weeks (Donia et 
al. 2012). The in vitro expansion of TILs, however, has its special challenges 
as a result of the limited starting cell number. 
Current methods for the in vitro expansion of Tregs commonly use 300 
IU/mL (Putnam et al. 2013). In this study (II), Treg expansion was 
conducted under 1 000 IU/mL of IL-2. Studies addressing exhaustion or 
functional impairment of Tregs after excessive in vitro expansion have not 
been published. However, Tregs with a naïve-like phenotype have in vitro 
functionality that exceeds the potency of more effector-like Tregs (Hoffmann 
et al. 2006, Lamikanra et al. 2017). In the present study, Tregs were potent 
suppressors after expansion, therefore suggesting that a 2-week expansion 
using a very high level of IL-2 does not cause deterioration of Tregs derived 
from healthy donors. 
Other novel approaches for the production of early memory T cell 
enriched products are based on IL-7 and IL-15 induced homeostatic T-cell 
proliferation (Gargett and Brown 2015), signaling inhibitors that interrupt 
effector cell differentiation (Sabatino et al. 2016), or selection of less-
differentiated starting cell populations before expansion (Sommermeyer et 
al. 2016). The increase in early memory T cells using homeostatic cytokines 
instead of the commonly used IL-2 concentrations (100-300 IU/mL, (Cieri et 
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al. 2013, Xu et al. 2014, Gargett and Brown 2015)) is similar in magnitude to 
the increment demonstrated here by limiting IL-2 supplementation (5-30%). 
In a recent study, the use of IL-7 and IL-15 yielded 10-20% more TSCMs 
compared to expansions without any cytokine supplementation (Singh et al. 
2016). Singh et al. also revealed a simultaneous IL-7 and IL-15 induced 
decrease in TCM and, interestingly, an increase in TEff. 
T-cell expansion in low IL-2 concentration also provides other benefits in 
addition to the favorable cell composition.  First, compared to other 
approaches requiring complicated multistep processes, it offers a simple and 
cost-effective GMP-grade procedure for clinical use. Second, the safety 
profile of cells produced with methods that are based on clonal expansion is 
better known than with the more novel methods. The utilization of signaling 
inhibitors in conjunction with T-cell activation or homeostatic cytokines 
detached from the physiological homeostatic environment (e.g. signaling for 
‘space’) may also modify other characteristics of the cells. Furthermore, 
robust IL-2 or IL-15 signaling with concurrent viral activation of oncogenes 
has been linked to insertional mutagenesis (Newrzela et al. 2011). 
The appropriate clinical cell dose for T-cell therapies is not known and 
may depend on the cell phenotype in the product. Dose-escalation studies are 
needed to define the T-cell expansion conditions providing the best balance 
between cell subset composition and sufficient total cell number. 
The generation of TSCMs and CD4+ T cells 
The generation of TSCMs, a memory T-cell subset bearing superior 
proliferative capacity and ability to self-renew, was inconsistent over time 
and between expansions (I). TSCM generation and the expansion kinetics of 
the cultures were connected. The lack of TSCMs on day 10 was detected in 
cultures that displayed a slow T-cell proliferation during the first week of 
expansion. The subsequent intensive proliferation may be related to the 
presence of TSCMs later on day 20. Also, vice versa: when good proliferation 
was achieved during the first week of expansion, TSCMs were generated in 
cultures already before day 10 but then their proportion decreased by day 20. 
These results may imply that for product comparability, it is more important 
to follow the individual growth kinetics of the cells instead of limiting the 
production process to a beforehand defined length. This data illustrates the 
sensitivity of primary cell culturing and the challenges encountered in cell 
manufacturing. 
Considering the proposed progressive model, where memory T-cell 
generation is a stepwise process from more primitive cells to cells with 
increasing effector functions (Farber et al. 2014), it was surprising to find (I) 
that cultures initially deficient for the most primitive subsets, naïve and TSCM, 
later contained TSCMs. Also, only naïve T cells have been demonstrated to give 
rise to the memory stem cell population during in vitro T-cell expansion 
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(Singh et al. 2016). It is possible that those subsets were present at all times 
during expansion but only at low levels below the detection limit. 
Most in vitro expansion protocols seem to be incapable of generating 
TSCMs (CD95+CD45RO-CD45RA+CD27+, (Cieri et al. 2013, Xu et al. 2014, 
Gomez-Eerland et al. 2014, Gargett and Brown 2015)). Finding out the 
factors inducing the generation of TSCMs in the present system (I) would be of 
great interest both scientifically and with regard to production of adoptive T-
cell products. The TSCM formation was not dependent on the level of 
supplemental IL-2. Signals provided by IL-7, IL-15, and IL-21 (Gattinoni et 
al. 2011, Cieri et al. 2013, Sabatino et al. 2016) may be central to the 
generation of TSCMs and TSCM-like cells, a subset not detected in blood but 
which has been depicted in in vitro expansions 
(CD95+CD45RO+CD45RA+CD27+, Figure 6, (Cieri et al. 2013, Xu et al. 2014, 
Gomez-Eerland et al. 2014, Gargett and Brown 2015)). T cells are not known 
to produce IL-7 or IL-15 but IL-21 and IL-9 are secreted by activated CD4+ T 
cells (Rochman et al. 2009). IL-9 supports T-cell survival and is produced in 
the late phases of the T-cell response (Rochman et al. 2009, Parrot et al. 
2016). Cytokine secretion was not measured in our expansion cultures. 
However, based on the importance of CD4+ cells for the T-cell memory 
formation (Janssen et al. 2003, Shedlock and Shen 2003) and correlation 
between the clinical T-cell persistence and the numbers of CD4+ T cells in cell 
products (Louis et al. 2011), we hypothesize that the generation of TSCMs is 
dependent on CD4+ T-cell derived factors produced after these cells’ peak 
proliferation during immune activation. 
Assuming that in vitro generated early memory T cells have a similar 
homing capacity to their physiological counterparts, they will not enter 
peripheral tissues. Rather, they will be activated if they meet their target 
antigens in lymphoid organs. This event depends on efficient Ag-
presentation by APCs or the presence of target cells in lymphoid tissues. 
Thus, the clinical success of early memory cell enriched T-cell products in 
cancer may be highlighted in hematological malignancies. Clinical data from 
trials treating patients with non-hematological tumors is pending (Gomez-
Eerland et al. 2014, Gargett et al. 2016). 
Regarding the growing interest in CD4+ T cells in adoptive T-cell therapy 
(Dudley and Rosenberg 2003, Hunder et al. 2008, Dudley et al. 2013, Tran et 
al. 2014, Sommermeyer et al. 2016), our data indicate that limiting the length 
of in vitro expansion helps to preserve CD4+ T cells in mixed CD4+/CD8+ T-
cell expansions. 
The functional potency of Tregs following in vitro expansion 
Tregs were slightly better immunosuppressors after in vitro expansion than 
their fresh, non-expanded counterparts (II), in line with earlier reports 
obtained in humans and animal models (Hoffmann et al. 2004, Chai et al. 
2008, Theil et al. 2015). The lower Treg content in the product is one 
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explanation for the weaker performance by fresh cells. Cellular impurities 
result from the difficulties in dissociating Tregs from conventional T cells. 
Although different in function, Tregs are, in essence, similar to other T cells. 
They circulate in the body, constantly monitoring their environment, need 
activating signals to launch their functions, and have different phenotypes in 
resting and activated states. Considering this, it makes sense that T cells and 
Tregs exhibit the same surface markers and are therefore difficult to separate 
from each other in practice. Most clinical Treg methods use magnetic bead-
based selection (CD4+CD25+) instead of FACS sorting (CD4+CD25+CD127-
/low) due to much easier applicability in GMP. As a consequence, the purity of 
isolated, non-expanded Tregs can be lower (Seddiki et al. 2006, Liu et al. 
2006) but during subsequent expansion, Tregs are enriched. However, the 
stringent FACS-based Treg selection used in our study points to other 
reasons than impurities behind the differences between expanded and fresh 
cells. 
The studies reported here demonstrate that expanded Tregs expressed 
higher levels of CTLA4, which also predicted more potent Treg function. 
CTLA4 is known to play a key role in the immunosuppressive function of 
Tregs (Sakaguchi et al. 2009). However, blocking the function of CTLA4 only 
had a moderate effect on the Treg-mediated inhibition of fresh Tregs. After 
expansion, even the slight influence seen by CTLA4 blockade disappeared. 
These findings suggest that the Treg population obtained by sorting was 
using CTLA4-mediated suppressive mechanism. However, CTLA4 was not 
irreplaceable for their function. In vitro T-cell expansion is based on 
activation of the cells through TCR. This activation can also arm other 
immunosuppressive mechanisms in Tregs, like inhibitory cytokines, in 
addition to CTLA4. Versatile mechanisms would be more readily usable and 
could better compensate for each other. 
In conclusion, in vitro expansion of Tregs is helpful, not only because it 
offers higher cell numbers for therapeutic use but also because the functional 
potency of Tregs is strengthened. The activating nature of T-cell expansion 
presumably upregulates a wide range of function-related molecules. These 
results provide support for the development of clinically feasible in vitro 
expansion methods for Tregs. 
5.2 Role of the CTLA4 receptor and its soluble isoform 
in immunology (II & III) 
CTLA4 isoforms in Tregs 
Study (II) showed that the expression of RNA encoding for the CTLA4 
receptor is linked to enhanced Treg immunosuppression. In contrast, the 
level of sCTLA4 showed a negative correlation. These results suggest, in line 
with other reports (Gerold et al. 2011, Ward et al. 2013), that the function of 
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CTLA4 receptor is more important than the function of sCTLA4 and  is likely 
to be sufficient for the immunosuppressive function of Tregs, even without 
the sCTLA4 isoform. 
Gerold et al. were able to segregate the function of sCTLA4 from the 
CTLA4 receptor by specific silencing of the soluble isoform in a T1D mouse 
model (Gerold et al. 2011). Tregs deficient for sCTLA4 could not inhibit the 
expression of CD86 on DCs as efficiently as cells expressing sCTLA4. The 
elimination of sCTLA4 impaired the in vivo function of Tregs, but the 
functional in vitro effect was only seen with high responder cell to Treg ratios 
(≥ 1:0.2). Interpretation of the studies conducted in mice is complicated by 
the presence of a third CTLA4 isoform lacking the extracellular domain, 
ligand-independent CTLA4 (liCTLA4), which is absent in humans. The 
importance of sCTLA4 was only seen when higher amounts of liCTLA4 were 
simultaneously produced. sCTLA4 elimination delayed the onset of 
autoimmune disease, but a direct comparison to the CTLA4 receptor deletion 
was not made. The complete loss of CTLA4 gene in mouse Tregs has 
spontaneous, fatal consequences (Wing et al. 2008). 
Ward et al. addressed the function of sCTLA4 in human Tregs (Ward et al. 
2013). First, using an sCTLA4-specific novel antibody, they demonstrated 
human Tregs to be prominent producers of secreted sCTLA4 protein. Specific 
sCTLA4 blocking reduced the inhibitory function of Tregs, which was 
stronger with higher responder to Treg ratios (1:0.5 and 1:0.1) in contrast to 
1:1 cultures that provide more cell contact. Unfortunately, no comparison to 
CTLA4 receptor blocking was conducted. 
Together, these studies imply that sCTLA4 functions as an inhibitory 
molecule in Tregs. The function of sCTLA4 seems to matter only when cell 
contact between Tregs and their target cells is scarce, suggesting a secondary 
role compared to the CTLA4 receptor. However, inside the body, in the 
natural physiological context, the availability of contact between Tregs and 
their targets is not known. 
sCTLA4 in immune response 
When sCTLA4 was discovered, it was thought to be present mainly in resting 
T cells and its expression to be repressed by T-cell activation (Magistrelli et 
al. 1999, Oaks et al. 2000). Our results show that upon the induction of Treg 
cell expansion by T-cell activating factors (CD3/CD28 beads, II) and TCR-
complex mediated activation of CD4+ T cells (III), the sCTLA4 expression is 
in fact upregulated. Other reports confirm these findings (Perez-Garcia et al. 
2013, Ward et al. 2013). Only exceptionally strong T-cell stimulation leads to 
the downregulation of sCTLA4 (Ward et al. 2013). The possibility that 
sCTLA4 production is suppressed due to strong but incomplete activation 
conducted without CD28 cosignal has not been studied. Even so, the idea 
that in resting state sCTLA4 would function as a regulator of immune 
activation or T-cell homeostasis is not a plausible explanation due to the 
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activation-related expression profile. Compared to the receptor, a similar but 
possibly distinct role in activated T cells is suggested for sCTLA4 by the 
concurrent expression and the recently accepted inhibiting function (Oaks et 
al. 2000, Huurman et al. 2007, Simone et al. 2009, Ward et al. 2013). 
The downregulation of CD28 ligands on the surface of APCs is the only 
known mechanism for sCTLA4 (Huurman et al. 2007, Gerold et al. 2011). 
Another potential mechanism is the induction of IDO via CD80/CD86 
signaling. Other mechanisms used by the CTLA4 receptor, like trans-
endocytosis of CD28 ligands from the surface of APCs or direct inhibitory 
signaling in T cells themselves, cannot be employed by a soluble factor. 
However, the expression of CD80 is induced on activated T cells (Chen and 
Flies 2013). Therefore, one possibility is that sCTLA4 binds its ligands on the 
surface of other T cells - or even in an autocrine manner. On the other hand, 
by using soluble CTLA4 instead of the receptor, a T cell could avoid potential 
intrinsic inhibitory signals but still be able to inhibit other cells, a mechanism 
that would suit regulatory cells. As a secreted protein sCTLA4 at least has a 
wider functional range compared to the CTLA4 receptor, which functions in 
cell contact. 
Interestingly, sCTLA4 is secreted by certain tumor cell lines (Ward et al. 
2014). Furthermore, effector T cells or Tregs that infiltrate into the tumor 
could secrete sCTLA4 in a manner similar to the increased expression of 
checkpoint molecules (CTLA4, PD-1). In a mouse model of melanoma, 
specific targeting of sCTLA4 improved the tumor control as efficiently as the 
targeting of total CTLA4 (Ward et al. 2013). Therefore, an inhibitory role in 
the tumor microenvironment has also been proposed for sCTLA4. 
Lastly, if sCTLA4 is present in the blood of autoimmune or cancer 
patients (Oaks and Hallett 2000, Mayans et al. 2007, Simone et al. 2009, 
Tector et al. 2009, Cao et al. 2012, Simone et al. 2012, Esposito et al. 2014), it 
could serve as a biomarker for the disease progress or therapy (Ward et al. 
2014). 
In summary, the role and functional mechanisms for sCTLA4 are far from 
clear. However, it is evident that sCTLA4 plays a part in the regulation of 
immune response and is an attractive molecule in immune-related diseases, 
like autoimmune disorders or cancer. 
5.3 Exploring the CTLA4-mediated functional effects of 
T-cell cosignaling receptor gene variation (III) 
Upon T-cell activation, the expression of both CTLA4 isoforms was regulated 
in the same way by one polymorphism (IVS1+173T/C), but alternative 
splicing was affected by genetic variation in CT60G/A polymorphism in 
resting cells only. In our extended genetic analysis, two additional 
polymorphisms were associated with CTLA4 expression in a similar manner: 
upon stimulation one polymorphism (rs11571300) influenced the expression 
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of both isoforms but another was linked to altered sCTLA4 levels only 
(rs231755, (Haimila et al. 2009)). These results show that genetic variation 
affects CTLA4 expression differently in resting and activated T cells. 
Substantial evidence indicates that genetic variation in the gene segment 
containing CD28, CTLA4, ICOS, and PD-1 genes is associated with 
susceptibility to many immune-related disorders, and this association is 
presumed to derive from differences in gene expression. To use functional 
genetics in personalized medicine, the effects must be validated and be 
concordant between studies.  However, the numerous genetic disease 
association studies, even systematic whole genome screenings and those 
utilizing genetic tools such as expression Quantitative Trait Locus (eQTL) 
databases, as well as the functional genetic studies conducted to date, reflect 
the complexity of CD28 family cosignaling receptors at multiple levels. First, 
the complex and strong genetic linkage disequilibrium in the region 
obfuscates the identification of disease-linked genetic polymorphisms 
(Haimila et al. 2004). Second, the intricate regulation of CTLA4 protein 
expression in general in addition to the in part discrete genetic regulation of 
the splicing isoforms, and third, the complex functions of CTLA4, with both 
cell-intrinsic and extrinsic effects wrought via multiple mechanisms, make 
the design of functional studies difficult. Lastly, the fact that CTLA4 plays 
different roles in immunology depending when and where anatomically and 
on which type of cell it is expressed complicates the interpretation of the 
results. These levels of complexity are not separate from each other but 
intertwined. 
As an indication of the current status of the functional CTLA4 genetics, it 
can be noted that there is no consensus on what the immune disorder-
associated CTLA4 characteristics are. Some suggest that the genetic disease-
predisposing phenotype is CTLA4 deficient (Kouki et al. 2000, Ligers et al. 
2001, Anjos et al. 2002, Maurer et al. 2002, Howard et al. 2002) and others 
that CTLA4 is over-expressed (III, (Wang et al. 2002, Anjos et al. 2004, 
Haimila et al. 2009, Perez-Garcia et al. 2013). The third group of data points 
to the deficient expression of the sCTLA4 isoform (III, (Ueda et al. 2003, 
Atabani et al. 2005, Perez-Garcia et al. 2007, Haimila et al. 2009)). 
Two recent publications demonstrated the clinical consequences of 
reduced CTLA4 expression (Kuehn et al. 2014, Schubert et al. 2014). Rare 
heterozygous mutations in the CTLA4 gene caused a severe disorder (CTLA4 
haploinsufficiency with autoimmune infiltration, CHAI) with functionally 
impaired Tregs and disturbed T and B-cell homeostasis. In the affected 
families, several polymorphisms led to the same outcome, though not in all 
the family members carrying the mutation. 
eQTL databases established during the past few years provide a powerful 
and systematic tool for analyzing the effects of gene variation on gene 
expression. Table 9 shows a list of genetic polymorphisms that were found to 
regulate the CTLA4 gene in blood according to the eQTL database of Westra 
et al. (Westra et al. 2013). If we want to proceed toward personalized 
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medicine by utilizing gene markers for CTLA4, we should first know the net 
effect of all these variants. 
Considering the immune regulated nature of CTLA4 expression and our 
results demonstrating different functional effects in resting and activated T 
cells, the most relevant variants may be found only using stimulated samples. 
In line with this, the polymorphism influencing the CTLA4 expression in 
stimulated cells only (IVS1+173T/C, rs10932029) or the one identified in our 
extended study (rs11571300, (Haimila et al. 2009) are not found in the eQTL 
database (Table 9). Therefore, eQTL data that are based on in vitro 
stimulated samples, or patient material would better reflect the physiological 
context where the genes, and cells expressing them, function. Such databases 
are emerging (Ye et al. 2014, Peters et al. 2016, Li et al. 2016). We have also 
produced a small eQTL bank based on activated and non-activated T cells 
from ~50 blood donors (Saavalainen et al. unpublished). 
The possibility that direct CTLA4 protein measurement in cells, and in 
Tregs particularly, can be applied in personalized medicine could be 
explored. It might be simpler to measure the functional outcome that 
apparently causes the immune disturbance than it is to reveal the very 
complex and possibly somewhat individual genetics behind it (Kuehn et al. 
2014, Schubert et al. 2014). Potential scenarios for the utilization of the 
CTLA4-related personalized medicine in cell therapies can be envisioned. For 
example, virus-specific T-cell products derived from donors with a low 
expression of CTLA4 may be associated with a higher risk for unwanted T-
cell activity, such as GVHD, and hence may not be suitable for all patients. 
To conclude, elucidating the functional effects of genetic variation on 
CTLA4 is complex and the subsequent impacts on immunity are not yet 
known but are most likely highly context-dependent. 
 
Table 9 Genetic variation nearby the CTLA4 gene (cis) affecting CTLA4 expression in 





The aim of these studies was to test how in vitro cell expansion influences the 
characteristics of human regulatory T cells and T cells with potent effector 
functions, and to assess the significance of CTLA4 isoforms and the role of 
genetic variation in controlling CTLA4 expression. 
The expansion of T cells under reduced cytokine conditions produced a 
higher percentage of early memory T cells, which likely perform better in 
adoptive T-cell therapy. Compared to other approaches to generate memory 
T-cell enriched products, the method described here is technically simpler 
and more cost-efficient, and its safety is better known. Also, this method is 
capable of generating TSCMs, the T cells with the highest survival potency. The 
functional potency of Tregs was associated with the RNA levels of the CTLA4 
receptor and was slightly strengthened by the in vitro expansion. Therefore, 
the expansion of Tregs is beneficial in two ways. The number of Tregs in the 
blood, which is originally low, can be multiplied, and the cells simultaneously 
gain a better inhibitory capacity. Determining a good T-cell product for 
clinical use is, however, not straightforward. A balance between the cell 
phenotype or function and cell number is required, and these properties are 
often interdependent. Future studies addressing this balance are needed. 
The soluble isoform, sCTLA4, seems secondary to its receptor 
counterpart, both in Treg function and in expression. Although the 
regulation of the isoforms was similar in response to T-cell activating signals, 
distinct features were seen in resting CD4+ T cells, in which genetic variation 
played a role, and on the other hand, in expanded Tregs compared to fresh 
Tregs. Further research is required to elucidate the role of sCTLA4 and the 
immunological impact of gene variation in the CTLA4 gene region. 
In conclusion, the studies presented in this thesis provide new knowledge 
that can be utilized in the production of therapeutic T cells and broaden the 
knowledge base for potential CTLA4-based personalized medicine. As the T-
cell expansion method described here, and the observations made using it, 
are directly applicable in T-cell manufacturing, these research results may 
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